Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

# PING AN HEALTHCARE AND TECHNOLOGY COMPANY LIMITED 平安健康醫療科技有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 1833)

# ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024

The board of directors (the "Board") of Ping An Healthcare and Technology Company Limited (the "Company") is pleased to announce that the unaudited interim results of the Company and its subsidiaries (the "Group") for the six months ended 30 June 2024. This announcement, containing the full text of the 2024 interim report (the "Interim Report") of the Company, complies with the relevant requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") in relation to information to accompany preliminary announcements of interim results.

The Group's interim results for the six months ended 30 June 2024 have been reviewed by the audit and risk management committee of the Company.

This announcement will be published on the website of the Stock Exchange at www.hkexnews.hk and the website of the Company at www.pagd.net. The Interim Report for the year ended 30 June 2024 will be published on the aforesaid websites of the Stock Exchange and the Company and will be sent to the Company's shareholders in due course.

By order of the Board

Ping An Healthcare and Technology Company Limited

Mr. Dou Li

Chairman

Hong Kong, 20 August 2024

As at the date of this announcement, the Board comprises Mr. Dou Li as the Chairman and the executive Director and Mr. Jun Wu as the executive Director; Mr. Michael Guo, Ms. Fangfang Cai, Ms. Xin Fu and Mr. Ziyang Zhu as non-executive Directors; and Mr. Yunwei Tang, Mr. Tianyong Guo and Dr. Wing Kin Anthony Chow as independent non-executive Directors.

# **Contents**

| Corporate information                                  | 2  |
|--|----|
| Chairman's Statement                                   | 4  |
| Management Discussion and Analysis                     | 8  |
| Other Information                                      | 23 |
| Report on Review of Interim Financial Information      | 32 |
| Interim Condensed Consolidated Income Statement        | 33 |
| Interim Condensed Consolidated Statement               |    |
| of Comprehensive Income                                | 34 |
| Interim Condensed Consolidated Statement               |    |
| of Financial Position                                  | 35 |
| Interim Condensed Consolidated Statement               |    |
| of Changes in Equity                                   | 37 |
| Interim Condensed Consolidated Statement of Cash Flows | 38 |
| Notes to the Interim Condensed Consolidated            |    |
| Financial Information                                  | 39 |
| Definitions  | 73 |
|  |    |
|  |    |

## **Corporate Information**

#### **Directors**

#### **Executive Directors**

Mr. Dou Li (Chairman)

Mr. Jun Wu

#### **Non-executive Directors**

Mr. Michael Guo

Ms. Fangfang Cai

Ms. Xin Fu

Mr. Ziyang Zhu

#### **Independent Non-executive Directors**

Mr. Yunwei Tang

Mr. Tianyong Guo

Dr. Wing Kin Anthony Chow

### **Audit and Risk Management Committee**

Mr. Yunwei Tang (Chairman)

Mr. Tianyong Guo

Ms. Fangfang Cai

#### **Nomination and Remuneration Committee**

Mr. Tianyong Guo (Chairman)

Mr. Yunwei Tang

Dr. Wing Kin Anthony Chow

Mr. Michael Guo

#### **Sustainable Development Committee**

Dr. Wing Kin Anthony Chow (Chairman)

Mr. Dou Li

Ms. Xin Fu

## **Authorized Representatives**

Mr. Dou Li

Mr. Cheng Liu

### **Company Secretary**

Mr. Cheng Liu

# Principal Share Registrar and Transfer Office

Maples Fund Services (Cayman) Limited

PO Box 1093, Boundary Hall

Cricket Square

Grand Cayman, KY1-1102

Cayman Islands

## **Hong Kong Share Registrar**

Computershare Hong Kong Investor Services Limited

Shops 1712-1716, 17/F, Hopewell Centre

183 Queen's Road East

Wanchai

Hong Kong

#### **Auditor**

PricewaterhouseCoopers

Certified Public Accountants and Registered PIE

Auditor

22/F, Prince's Building

Central

Hong Kong

## **Registered Office**

The offices of Maples Corporate Service Limited

PO Box 309

Ugland House

Grand Cayman, KY1-1104

Cayman Islands

# **Head Office and Principal Place** of Business in China

5-8/F, Building B, INNO KIC

No. 298 Guo Xia Road, Yangpu District

Shanghai

PRC

## **Corporate Information**

# **Principal Place of Business in Hong Kong**

5/F, Manulife Place 348 Kwun Tong Road Kowloon Hong Kong

## **Principal Correspondent Bank**

Bank of China (Hong Kong) Limited 1 Garden Road Central Hong Kong

#### **Stock Code**

1833

## **Company's Website**

www.pagd.net

## **Listing Date**

4 May 2018

## **Legal Advisors**

#### As to Hong Kong law:

DLA Piper Hong Kong 25th Floor, Three Exchange Square 8 Connaught Place, Central Hong Kong

#### As to PRC law:

Haiwen & Partners 2605, Jing An Kerry Centre Tower 1 No. 1515 Nan Jing West Road Shanghai PRC

### As to Cayman Islands law:

Maples and Calder (Hong Kong) LLP 26/F, Central Plaza 18 Harbour Road Wanchai Hong Kong

# **Chairman's Statement**



MR. DOU LI

Chairman of the Board and Chief Executive Officer

The healthcare industry is a crucial component of the national economy of China and plays a vital role in safeguarding the health and life safety of the public. In recent years, the healthcare industry has been undergoing innovative transformations driven by new quality productive forces, and with technological advancements as its driving force, the healthcare industry is expecting even broader development. As people's living standards improve, their health awareness is evolving, updating, and upgrading, and health belief has shifted from a focus on treating existing diseases to preventing them. Such increased health literacy has led to a growing demand for healthcare services. China's aging population has entered a rapid development stage. According to projections by the National Health Commission of China, by 2035, the population aged 60 and above will exceed 400 million, accounting for over 30%1 of the total population. As China's aging population grows at an accelerated pace and life expectancy lengthens due to improved living standards and technological advancements, people are paying more attention to the diverse survival security needs in the era of longevity. Against the backdrop of increasing market demand for health and senior care services and the continuous advancement of healthcare reforms. China's health and senior care industries are expected to maintain sustained and steady growth, with vast market potential, presenting valuable development opportunities for Ping An Health, and we believe that extensive engagement in the healthcare and homebased senior care sectors will bring continuous value growth to Ping An Health.

The data is from the transcript of the press conference held by the National Health Commission of China on 20 September 2022.

Only by truly connecting with and understanding customers can we find the core solutions. As customer needs expand from healthcare to health and senior care, as a flagship in Ping An Group's health and senior care ecosystem, Ping An Health boasts abundant health and senior care service payer resources (F-end commercial insurers/financial service providers, B-end enterprises, etc.), widespread service provider networks, well-developed service standards, and strong support from Ping An Group's ecosystem. Acting for payers and integrating providers, Ping An Health has become a professional, comprehensive, high-quality, one-stop health and senior care management service provider.

2024 is full of opportunities and challenges for Ping An Health. In a highly volatile market environment, the public is becoming more rational in planning their health and senior care consumption. How to achieve long-term profitability and maintain sustainable development under such circumstances become a key test of a company's strength. During the Reporting Period, we remained strategically determined, and reinforced our positioning as a flagship in Ping An Group's health and senior care ecosystem, unlocking more synergies between health care and insurance. With steady growth in F-end business, rapid development of B-end business, continuous optimization of resource allocation, as well as continuous improvements in operational efficiency driven by AI, informatization and other technologies, Ping An Health has achieved profitability during the Reporting Period. The significant turnaround in performance demonstrates the remarkable and encouraging results of the implementation of the Company's Strategy 2.0 Continuum, and is also attributable to the trust and continued support of all our shareholders.

During the Reporting Period, Ping An Health continued to focus on the development of family doctors and senior care concierges, and has now become a leading health and senior care service provider in China. In June 2024, Ping An Health announced a comprehensive upgrade of its family doctor service brand, "Ping An Family Doctor." With upgrades in service teams, standards, models, and capabilities, the newly upgraded "Ping An Family Doctor" has formed a "1-1-3-12" one-stop, proactive health management services system, which includes 1 team of professional and authoritative family doctors, 1 world-class standard service process, 3 proactive health management service solutions, and 12 scarce medical resources. Driven by various factors such as an aging population, widespread adoption of mobile internet, improving living standards, and growing diversified and personalized health needs, people's health needs have long gone beyond diagnosis and treatment when they are sick. Instead, they seek a comprehensive one-stop healthcare service solution that covers health education, prevention, early diagnosis, treatment and rehabilitation. "Ping An Family Doctor" front-loads its proactive, end-to-end services while consolidating its family doctor service system, continuously enhancing its service capabilities, and remains committed to providing "proactive health management, effective chronic disease control, and whole-course disease management" for users. The upgrade of the "Ping An Family Doctor" brand is in pace with the times, in line with the direction of industry development and dedicated to continuously "solving problems" to meet diverse, unique customer needs. During the Reporting Period, the Company had over 14 million users with access to family doctor service benefits, and the annualized usages of family doctor services were over 4 times per capita, up by 8% from 31 December 2023. The proactive service rate reached 100%.

#### **Chairman's Statement**

During the Reporting Period, Ping An Health continued to strengthen the construction of service systems in medical care, housing, nursing and entertainment scenarios, empowering the principal business of Ping An Group and enhancing customer experience. In March 2024, Ping An Health, together with its partners, jointly established the "Ping An Concierge Senior Care Service Alliance (平安管家 安全享老服務聯盟)" and launched the "5-7-3 Home Safety Renovation Service (573 居家安全改造服務)". Parties involved jointly set up service standards and a supervision framework to meet the elderly's home safety needs, facilitating the further exploration in the "insurance + home-based senior care" model. On the one hand, Ping An Group's empowerment in the F-end financial payer resources is also where Ping An Health's unique competition lies. Based on user profiles and needs of different financial businesses, Ping An Health has conducted business cooperation with Ping An Life Insurance, Ping An Property & Casualty Insurance and Ping An Health Insurance, such as "product integration," "benefit procurement," and "value-added services," which effectively attracted the customer base from Ping An Group's financial business and successfully converted them into Ping An Health's own users, enhancing customer stickiness. On the other hand, the comprehensive "3-in-1" senior care concierge system integrating smart concierges, daily life concierges, and doctor concierges provides 24/7 online assistance to customers, and expands the coverage of the high-quality "online, in-store and home/company delivered" service network, committing to delivering customers with the best cost-effective service and providing differentiated competitive strengths for Ping An Group, allowing customers easier access to and gain availability to insurance and helping Ping An Group's integrated finance business with user acquisition, retention, and conversion. Ping An Group's retail integrated financial customers using services from its health and senior care ecosystem had 1.6 times more contracts and 3.6 times<sup>2</sup> higher AUM per capita than the non-users of these services as of 31 March 2024.

During the Reporting Period, Ping An Health continued to deepen its managed care strategy and promoted the optimization and upgrading of business models and service processes through technological innovation, which enabled dual enhancement in operational efficiency and service quality, effectively enhanced the quality of health care services, improved operational efficiency and optimized patient experience. The application of the Ping An Medical Master (平安醫博通®), a self-developed large multi-modal medical AI model, enables Ping An Health's family doctors to promptly and accurately obtain key health information of users and prepare high-quality personalized healthcare service solutions. During the Reporting Period, we also upgraded the Ping An Doctor's Home™ (平安醫家人™), a doctor's workbench, on all fronts to continuously empower the improvement of health care service capabilities, which has now realized Al-enabled real-time medical insight assistance. Al-empowered data collection and user health profile generation, and quality control for key points in online consultations, such as risk warning for critically ill patients, cumulative medication risk warning for patients, prescription review, and medical record integration. Driven by technologies, the service operation efficiency, user experience and medical service capabilities were further enhanced, the satisfaction rate of users for online consultations exceeded 98%, and the proportion of Grade-A electronic medical records hit 99.8%, effectively resolving key problems such as knowledge update lag and poor health management continuity prevalent in traditional family doctor services. Looking ahead, Ping An Health will continue its efforts in developing AI and related use cases to raise the efficiency and quality of health care services, and to facilitate the digital and intelligent transformation of itself and industry peers.

#### **Chairman's Statement**

With the mission of "bridging doctors and patients with professionalism and safeguarding everyone's health", Ping An Health has been pursuing the goal of providing every enterprise with a harmonious workplace, every family with a dedicated doctor, and every user with a safe and healthy life. Ping An Health, rooted in the health and senior care service sector, has been rated Grade A by MSCI ESG for three consecutive years, ranking among the top in the health care service industry. Adhering to business for good, we organically incorporated ESG concepts into our products and services, comprehensively upgraded "Ping An Family Doctor" (平安家醫), a family doctor service brand, and unveiled our one-stop active health management system and user service commitment. Such innovative service model meets the growing demand for medical and healthcare services from the public, and actively promotes the transformation and upgrading of medical and healthcare services from "treatment" to "management", ushering in a new chapter for the coordinated development of health and senior care business and insurance business. Insisting on shouldering social responsibility and organically incorporating ESG concepts into the development of medical and healthcare ecosystems, Ping An Health has developed a health care services platform with unified interfaces that provides access to online health care for various partners to standardize service delivery and share capabilities with customers and fosters coordinated development of the industry. In April 2024, Ping An Health officially became a participant in the United Nations Global Compact, marking the international recognition of Ping An Health's long-term efforts to actively fulfill its social responsibilities. Ping An Health's participation not only underscores Ping An Health's strong commitment to the global sustainable development goals, but also demonstrates its determination to integrate international best practices into its corporate culture and operations.

Our journey is abound with ambitious goals, with opportunities and challenges coexisted. What we can do is to continuously create value for shareholders by making continued efforts and insisting on innovation. As a flagship in Ping An Group's health and senior care ecosystem, Ping An Health makes all-out efforts to implement the "integrated finance + health and senior care" strategy of Ping An Group, helps its customers realize the value proposition of "worry-free, time-saving and money-saving" by continuously developing a Chinese "managed care model", builds solid barrier and moat in health and senior care resources, improves products with "ingenuity" and establishes reputation with quality to build a sustainable business model, ensuring sustained high-quality development. We believe that Ping An Health will enjoy a brighter future.

#### Mr. Dou Li

Chairman of the Board and Chief Executive Officer Hong Kong, 20 August 2024

As a flagship in Ping An Group's health and senior care ecosystem, and an integral part of the Group's "managed care model," Ping An Health boasts abundant health and senior care service payer resources (F-end commercial insurers/financial service providers, B-end enterprises, etc.), widespread service provider networks, well-developed service standards, and strong support from Ping An Group's ecosystem. Acting for payers and integrating providers, Ping An Health has become a professional, comprehensive, high-quality, one-stop health and senior care management service provider.

In respect of providers, Ping An Health integrates online and offline health and senior care resources to further expand its service networks. By centering on family doctors and senior care concierges, Ping An Health strives to provide users with premium service experience featuring "fast diagnosis for minor illnesses, standardized management for chronic diseases, and precise referral for major illnesses."

In respect of payers, Ping An Health provides full-lifecycle health and senior care services for users (e.g. policyholders) of Ping An Group's integrated finance business (F-end payers) by integrating health and senior care service benefits with financial/insurance products, in an effort to improve their health. By doing so, Ping An Health facilitates Ping An Group's "heartwarming financial services," achieving synergistic development with Ping An Group's integrated finance business.

Meanwhile, Ping An Health provides professional, comprehensive, high-quality, one-stop corporate health management services for corporate clients (B-end payers). By improving health of their employees, Ping An Health helps cut health care expenses paid by its corporate clients. Thus, Ping An Health assists enterprises in creating healthy workplaces and enhancing employee productivity, which facilitates a shift in the value of corporate health management plans, from employee benefit cost reduction to worthwhile investments.

## **Key Financial Data**

|  | Unaudited Six months ended 30 June |                 |                     |  |  |  |
|--|------------------------------------|-----------------|---------------------|--|--|--|
|  | 2024<br>RMB'000                    | 2023<br>RMB'000 | Year-on-year change |  |  |  |
| Revenue  | 2,093,449                          | 2,222,177       | -5.8%               |  |  |  |
| Cost of sales                                    | (1,419,651)                        | (1,506,815)     | -5.8%               |  |  |  |
| Gross profit                                     | 673,798                            | 715,362         | -5.8%               |  |  |  |
| Selling and marketing expenses                   | (366,722)                          | (450,346)       | -18.6%              |  |  |  |
| Administrative expenses                          | (394,613)                          | (756,671)       | -47.8%              |  |  |  |
| - Including: research and development expenses   | (161,333)                          | (331,590)       | -51.3%              |  |  |  |
| Other income                                     | 18,284                             | 55,274          | -66.9%              |  |  |  |
| Other gains – net                                | 27,737                             | 79,291          | -65.0%              |  |  |  |
| Finance income – net                             | 102,436                            | 115,242         | -11.1%              |  |  |  |
| Share of losses of associates and joint ventures | (268)                              | (2,415)         | -88.9%              |  |  |  |
| Profit/(loss) before income tax                  | 60,652                             | (244,263)       | N/A                 |  |  |  |
| Income tax expense                               | (23)                               | (604)           | -96.2%              |  |  |  |
| Net profit/(loss) for the period                 | 60,629                             | (244,867)       | N/A                 |  |  |  |
| Net profit/(loss) attributable to:               |                                    |                 |                     |  |  |  |
| – Owners of the Company                          | 56,648                             | (244,618)       | N/A                 |  |  |  |
| – Non-controlling interests                      | 3,981                              | (249)           | N/A                 |  |  |  |
| Non-IFRS measure:                                |                                    |                 |                     |  |  |  |
| Adjusted net profit/(loss)                       | 89,739                             | (249,267)       | N/A                 |  |  |  |

- During the Reporting Period, the Company recorded a total revenue of RMB2,093.4 million, representing a year-on-year decrease of 5.8% from RMB2,222.2 million in the first half of 2023. This was mainly attributable to changes in the model of certain business lines leading to delays in revenue recognition in the first half of 2024, as well as a high base in the first half of 2023 (ongoing realignment of the Company's business with low strategic synergies and contract fulfillment concentrated in the first half of 2023 due to some one-off factor).
- During the Reporting Period, the Company achieved steady growth in its strategic business, with revenue from F-end and B-end strategic business increasing by 19.7% year on year. Specifically, F-end revenue reached RMB1,115.2 million, representing a year-on-year increase of 3.4% from RMB1,078.1 million in the first half of 2023; B-end revenue reached RMB713.1 million, representing a year-on-year increase of 58.8% from RMB449.1 million in the first half of 2023.
- During the Reporting Period, gross margin recorded by the Company was 32.2%, on par with 32.2% in the first half of 2023.
- During the Reporting Period, the Company greatly boosted its productivity and cost efficiency. Expenses decreased markedly as the Company continued to optimize resource allocation and staffing, strengthen input-output management, and increase operational efficiency via informatization, digitization and AI empowerment. Specifically, administrative expenses reached RMB394.6 million, representing a year-on-year decrease of RMB362.1 million or 47.8%; and selling and marketing expenses reached RMB366.7 million, representing a year-on-year decrease of RMB83.6 million or 18.6%.
- During the Reporting Period, with steady growth in F-end business, rapid development of B-end business, continuous optimization of resource allocation, as well as continuous improvements in operational efficiency driven by AI, informatization and other technologies, the Company quickened its pace to achieve a turnaround, recording a profit of RMB60.6 million versus a loss of RMB244.9 million in the first half of 2023.

## **Key Operational Data**

|   | Six months ended 30 June |       |        |
|---|--------------------------|-------|--------|
|   | 2024                     | 2023  | Change |
| Paying users of strategic business (in million) | 17.7                     | 17.0  | 4%     |
| Including: F-end paying users (in million)      | 14.8                     | 13.9  | 7%     |
| B-end paying users (in million)                 | 2.6                      | 2.6   | 2%     |
| Number of B-end enterprises served              | 1,748                    | 1,198 | 46%    |

Note: 1. Figures may not match the calculation due to rounding.

- During the Reporting Period, Ping An Health's paying users of strategic business reached about 17.70 million, representing a year-on-year increase of about 4%.
- Specifically, paying users of F-end strategic business reached about 14.80 million, representing a year-on-year increase of about 7%; paying users of B-end strategic business reached about 2.60 million, representing a year-on-year increase of about 2%.
- The number of B-end enterprises cumulatively served reached 1,748, representing a year-on-year increase of about 46%.

## **Analysis of Main Business Operations**

During the Reporting Period, the Company reinforced its positioning as a flagship in Ping An Group's health and senior care ecosystem, unlocking more synergies between health care and insurance, and continuously improving strategic business. In addition, bolstered by continuously enhanced resource allocation efficiency and organizational efficiency, the Company achieved profitability.

#### Achieving steady business growth and profitability

During the Reporting Period, the Company saw a slight year-on-year decline in revenue. This was attributable to changes in the model of certain business lines leading to delays in revenue recognition in the first half of 2024 and a high revenue base in the first half of 2023 (ongoing realignment of business with low strategic synergies and contract fulfillment concentrated in the first half of 2023 due to some one-off factor). After the general completion of the realignment of business with low strategic synergies in 2023, the Company achieved sound development in its strategic business. Specifically, the Company achieved steady growth in F-end business, unlocking more synergies with Ping An Group; and rapid growth in B-end business, with strengthened cross-selling of products. In addition, benefiting from technology adoption of Al, informatization, etc. as well as optimization of resource allocation and input-output management, the Company saw continuous improvements in organizational productivity and operational efficiency, and a significant drop in expense ratio, and hence quickened its pace to achieve profitability.

### 2. Continuing to strengthen collaboration with Ping An Group and advance the managed care strategy

1) Payers for Managed Care

#### Ping An Group's integrated finance business (F-end)

Ping An Group continuously advances the strategy of "integrated finance + health and senior care." As a flagship in Ping An Group's health and senior care ecosystem, Ping An Health provides full-scenario health and senior care services for Ping An Group's integrated financial service customers, fostering closer collaboration with Ping An Group's integrated finance business, and advancing the managed care strategy.

On the whole, Ping An Health provides online/offline one-stop, 24/7 proactive health and senior care services for users of Ping An Group's integrated finance business including Ping An Life Insurance, Ping An Property & Casualty Insurance, Ping An Health Insurance, and Ping An Bank. In respect of products and services, Ping An Health diversifies its offerings in health and senior care based on user profiles and needs of different financial businesses. Through business models such as "product integration," "benefit procurement," and "value-added services," Ping An Health helps Ping An Group's integrated finance business with user acquisition, retention, and conversion. Ping An Group's retail integrated financial customers using services from its health and senior care ecosystem had 1.6 times more contracts and 3.6 times<sup>1</sup> higher AUM per capita than the non-users of these services as of 31 March 2024.

Under "insurance + service" and other models, Ping An Health works with Ping An Life Insurance to participate in policyholders' health management by further unlocking synergies between health and senior care services and the insurance business. During the Reporting Period, Ping An Health continuously expanded service scenarios and upgraded service capabilities, enhancing customer management through family doctors and senior care concierges. During the Reporting Period, paying users of the strategic business in cooperation with Ping An Life Insurance increased by about 20% year on year, with revenue rising by about 14% year on year.

The data is from Ping An Group's Q1 2024 Results.

In respect of service scenarios, Ping An Health is developing "insurance + home-based senior care" in addition to "insurance + health care" to offer, in collaboration with Ping An Life Insurance, one-stop, differentiated home-based senior care solutions centered on senior care concierges, covering scenarios including "medical care, housing, nursing and entertainment". Ping An Health officially launched the "Ping An Concierge Senior Care Service Alliance" jointly with partners and launched the "5-7-3 Home Safety Renovation Service" in March 2024. Parties involved jointly set up service standards and a supervision framework to meet the elderly's home safety needs. As of 30 June 2024, home-based senior care benefits were available in 64 cities across China, up by 10 cities from 31 December 2023, and the number of users with access to the benefits increased by about 50% from 31 December 2023. In addition, Ping An Health constantly optimized user service experience, with NPS up by 8.4 pps year on year. In doing so, Ping An Health further empowered Ping An Life Insurance to acquire customers and increase customer value.

In respect of service capabilities and customer development, Ping An Health has further upgraded its service framework for Ping An Life Insurance's users. Take "Ping An Zhen Xiang RUN Health Services Plan" for example. Ping An Health introduced a 6th tier of benefit in addition to the existing 5 tiers, leveraging exclusive family doctors to provide proactive, continuous health management services for Ping An Life Insurance's users and their family members. These doctors generally have a background in 3A hospitals, with an average of over 20 years of clinical experience. Moreover, the Company continues to enhance the development of high-value customers by providing innovative services including athome testing, life sciences and cancer screening, and proactive and targeted user operation centered on family doctors to improve stickiness and value of policyholders.

In addition, Ping An Health also strengthens collaboration with other payers including Ping An Health Insurance, Ping An Property & Casualty Insurance, and Ping An Bank to improve the breadth and depth of services for their users. For instance, Ping An Health is increasing the penetration and utilization of family doctor services among the policyholders of Ping An Health Insurance to help improve their stickiness and health outcomes. Meanwhile, Ping An Health has furthered collaboration with Ping An Property & Casualty Insurance on service scenarios by leveraging its strengths in online/offline health management service networks. Moreover, Ping An Health provides services including medical visit assistance for users of Ping An Bank and other integrated finance channels of Ping An Group, helping them with more effective customer acquisition and retention.

Thanks to the above improvements, the Company saw steady progress in its F-end strategic business. During the Reporting Period, paying users increased by 7% year on year. However, due to changes in the model of certain business lines leading to delays in revenue recognition, F-end revenue increased by 3.4% year on year to RMB1,115.2 million.

In the medium to long term, Ping An Health will further tap into the advantages of Ping An Group's integrated finance business (F-end) in customer segments and resources to increase the penetration of Ping An Group's integrated financial service customers, further expanding membership and enhancing customer operation. While helping Ping An Group's integrated finance business with customer acquisition and retention, Ping An Health aims to help improve the health of retail financial service customers through proactive, long-term, and highly sticky services such as chronic disease management, thus empowering insurers to control costs. Furthermore, Ping An Health will constantly strengthen user development by centering on family doctors and senior care concierges to enhance customer stickiness and conversion, thereby facilitating the Company's long-term development.

#### **Corporate clients (B-end)**

Ping An Health considers corporate health management a pivotal element within the Company's Strategy 2.0 Continuum and also a key engine of long-term growth. The Company is committed to providing professional, comprehensive, high-quality, one-stop corporate health management solutions to corporate clients (B-end), with the goal of enhancing employee health and wellbeing while helping enterprises to achieve better sustainable development.

In respect of customers and users, Ping An Health actively collaborates with corporate clients from Ping An Group's channels. The Company specifically targets the large and medium-sized enterprises that have substantial budget for corporate health management, clear employee health management plans, and a strong ability and willingness to pay. The Company offers comprehensive health management solutions tailored to their employees. Moreover, the Company proactively expands its own sales channels by leveraging experience and capability gained through collaboration with Ping An Group's channels.

As Ping An Health continues to expand its corporate client base through both Ping An Group's channels and the Company's own channels, the number of corporate clients served by the Company has grown rapidly. As of 30 June 2024, the number of enterprises cumulatively served increased year on year by about 46% to 1,748.

In respect of products and services, Ping An Health consistently improves its "Enterprise EZHealth" corporate health management product portfolio. The Company is committed to upgrading its offerings based on a deeper understanding of employees' health management needs. The Company aspires to meet diverse needs of various enterprises via a product and service matrix with differential advantages. Moreover, the Company continues to diversify online-merge-offline operations. For instance, the Company offers proactive health management and precisely recommends its products and services online based on employees' health records; the Company holds offline workplace health activities to provide specific medical and health services, making employees healthier and more satisfied.

With the "Health Checkup +" product as a pivotal entry point into the corporate health management sector, Ping An Health continues to enhance the market penetration of the "Health Management +" product via cross-selling initiatives. As of 30 June 2024, corporate clients using our "Health Checkup +" product increased by 48.2% year on year to 1,070 cumulatively, and corporate clients using our "Health Management +" product increased by 38.9% year on year to 771 cumulatively.

B-end strategic business development was strong thanks to the growth of high-quality corporate clients and the increase of product sales via cross-selling. Revenue from the B-end strategic business jumped by 58.8% year on year, reaching RMB713.1 million.

In addition, Ping An Health bolsters engagement and collaborations with Ping An Group's channels in the corporate business by adopting approaches such as the operation of an employee health benefit mall, thereby deepening its presence in the corporate health management sector.

#### Individual customers (C-end)

During the Reporting Period, the Company leveraged its upgraded family doctor services featuring family doctors and senior care concierges to strengthen tiered member development and increase both the number and the stickiness of members. Once user habits are formed, the Company is poised to make significant strides in its F2C/B2C strategy, thereby forging a second development curve.

#### 2) Membership Manager

Focusing on family doctors and senior care concierges under the "online, in-store, and home/ company-delivered" service network, Ping An Health provides full-scenario services throughout the entire user journey.

Family doctor membership has been the cornerstone of Ping An Health's unique competitive edge. The Company upgraded its "Ping An Family Doctor" brand in June 2024, introducing the "1-1-3-12" one-stop, proactive health management services system, namely one team of professional family doctors certified by Peking University International Hospital and guided by the World Organization of Family Doctors (WONCA), one 5A standard service process guided by the General Practice Branch of the Chinese Medical Association, three health management service solutions tailored to the needs of sub-healthy individuals, patients with chronic diseases, and people with medical conditions, and 12 scarce medical resources provided to those in need. After brand upgrading, "Ping An Family Doctor" provides ex ante, proactive, end-to-end services while consolidating its family doctor service system. To meet diverse, unique customer needs, "Ping An Family Doctor" provides "proactive health management, effective chronic disease control, and whole-course disease management" for users. During the Reporting Period, the Company had over 14 million users with access to family doctor service benefits, and the annualized usages of family doctor services were over 4 times per capita, up by 8% from 31 December 2023. The proactive service rate reached 100%.

Moreover, Ping An Health has intensified its efforts to develop a comprehensive "3-in-1" senior care concierge system. The system integrates smart concierges, daily life concierges, and doctor concierges, providing 24/7 one-stop solutions across 10 home-based senior care scenarios. During the Reporting Period, the Company offered over 600 home-based senior care services.

As of 30 June 2024, Ping An Health had about 50,000 in-house doctors and contracted external doctors in 29 specialties, including about 2,900 contracted renowned doctors. They provided full-scenario, multi-tiered health and senior care services to meet users' needs.

Ping An Health is dedicated to enhancing specialty services to bolster its medical service capabilities. The Company operates 23 specialty medical centers, covering 8 medical specialties, and standardizes solutions before, during and after medical consultation, ensuring refined management throughout the patient journey. For instance, in chronic disease management, the Company rolled out "three blockbusters", namely blood sugar control, blood pressure control, and body weight loss, and provided users with health records, tailored solutions, and end-to-end monitoring and guidance to significantly improve their health outcomes.

Moreover, Ping An Health continuously improves its mechanisms to ensure the "rapid, precise, and efficient" delivery of medical services. The Company gauges fulfillment of its service commitments using metrics such as responsiveness, customer feedback, efficiency in fulfilling service contracts, and service satisfaction. During the Reporting Period, the Company got five-star reviews for its medical consultation service from more than 98% of users.

#### 3) O2O Health Care and Senior Care Service Network

Ping An Health is steadfast in its effort to enhance the "online, in-store, and home/company-delivered" service network to improve service quality and user experience. While expanding the service network and improving service quality, the Company continuously consolidates its advantages in platform-based, large-scale service procurement to offer more cost-effective services. The Company undertakes to "provide immediate consultations and whole-process accompanying consultations, refund the price difference for over 300 common medicines if users overpay, and replace expired medicines". By doing so, the Company fosters a broader, high-quality, cost-effective health care and senior care service network

In respect of the medical service network, Ping An Health provides users with more integrated, superior, and cost-effective services by further pooling online and offline medical service resources and developing a one-stop service delivery system. As of 30 June 2024, the Company partnered with nearly 4,000 hospitals and 233 thousand pharmacies. Moreover, the Company actively supports China's "internet+" health care initiatives. During the Reporting Period, the Company provided access to online social health insurance payment in cities such as Dongguan, improving the medical and drug purchase experience for users covered by social health insurance.

In respect of the health service network, Ping An Health partnered with 104,000 health service providers and nearly 2,500 health checkup service providers as of 30 June 2024 to offer various products and services including health checkups, senior care, dental care, anti-aging care, and health and wellbeing.

Regarding the senior care service network, the Company partnered with over 120 senior care service providers that can provide over 600 home-based senior care services as of 30 June 2024. The Company undertakes to refund the price difference if users overpay as the real-time price comparison system is applied to the Company's core services.

#### 3. Improving efficiency and experience with technology adoption

During the Reporting Period, Ping An Health further bolstered its capabilities in informatization, digitization, and AI empowerment by stepping up R&D and tapping into Ping An Group's technological strengths. In doing so, the Company streamlined its business operation process and enhanced operational efficiency, thereby injecting fresh impetus into health and senior care management services.

Ping An Health keeps advancing its medical AI capabilities. During the Reporting Period, the Company developed a large multi-modal medical AI model Ping An Medical Master® based on five industry-leading medical databases on diseases, prescriptions, medical products, medical resources, and personal health covering about 37,000 diseases, 220,000 drug instructions, 1.43 million doctors, and 1.42 billion consultations. It also fully upgraded the doctor's workbench Ping An Doctor's Home™.

Al plays a critical role in Ping An Health's medical quality assurance, medical insight assistance, and user health profile generation, continuously empowering the Company's medical capability building and efficiency improvement. During the Reporting Period, Al-assisted chronic disease management improved by 90%, and the proportion of Grade-A electronic medical records hit 99.8%, and family doctors' service efficiency rose by about 30%. Meanwhile, Al was deployed to facilitate 100%-coverage quality assurance of online consultations, electronic medical records, and prescriptions to, thereby, drive up health care service quality.

Looking ahead, Ping An Health will continue its efforts in developing Al and related use cases to raise the efficiency and quality of health care services, and to facilitate the digital and intelligent transformation and upgrades of itself and the industry as a whole.

## Long-term Strategies and Management Outlook

Commercial insurers play an important role in "commercial insurance + health and senior care", representing one of the major payers for medical and health expenditures in China. According to the Report to 20th National Congress of CPC, China will further integrate commercial insurance with the basic social medical insurance programs at different levels, improve critical illness insurance and medical assistance schemes, and vigorously develop commercial medical insurance. The Report on Work of Government delivered by the State Council at the Second Session of the 14th National People's Congress in 2024 has pinpointed the priorities of health care services and medical insurance: to enhance social security and social services, to boost the silver economy, and to move ahead with establishing insurance schemes for long-term care. The Guiding Opinions of National Financial Regulatory Administration on Banking and Insurance Sectors' Improving Five Financial Priority Areas released in May 2024 point out the needs to accelerate the development of senior care finance. Specifically, efforts should be made to advance the third pillar of pension insurance by supporting pension-like products such as deposit, wealth management, and insurance; to expand the scope of pilot commercial pension projects; to diversify health insurance offerings with preferential tax treatment; to explore commercial health insurance products including long-term care and health management services; and to ramp up financial support for the health sector, senior care sector, and silver economy.

In corporate health management, enterprises have become another major payer for medical and health expenditures in China. The government has been summarizing and promoting the experience and best practices in the process of building healthy enterprises to further healthy enterprise and occupational health protection actions. Currently, under the disbursement accounts of Chinese enterprises, 5% of wages are disbursable on supplementary medical insurance, 14% on employee benefits, and 2% on trade union funds. Theoretically, the corporate health management market in China is expected to reach a potential size of over RMB3 trillion in the long run.

Regarding family doctor and health management services, the National Health Commission issued the Notice on Initiating Three-year Plan to Raise Health Literacy for All Citizens (2024-2027) in May 2024. Following that, the government of Shanghai released the Notice on Building Health Management Centers at Community Health Service Centers in Shanghai. Specific measures include improving the set-up of health management platforms, promoting the construction of the family doctor contract-signing service centers and chronic disease management support centers, and encouraging the introduction of third-party health management institutions. Likewise, Guangzhou Municipal Health Commission has been building a family doctor workshop to vigorously promote the Hong Kong model of family doctor training.

Seizing the opportunities presented by the above industry trends and national policies, Ping An Health will strengthen synergies with Ping An Group in further implementing the "managed care" strategy to develop a Chinese "managed care model". The Company will strengthen its synergies and mutual empowerment with Ping An Group by fully utilizing Ping An Group's strengths in customer base and resources in integrated finance (F-end) and corporate clients (B-end), and, more specifically, by reaching the vast commercial insurers, corporate clients, and retail customers of Ping An Group with service offerings. The Company is becoming increasingly valuable in empowering F-end payers to improve customer acquisition, customer retention, and expense control, and in empowering B-end enterprises to enhance employee health, thereby improving customer penetration, stickiness, and conversion (into paying users).

Meanwhile, Ping An Health will further strengthen the role of family doctors and senior care concierges as service hubs in providing users with one-stop health care services integrating quality online and offline resources, and adopt a more proactive approach towards the tiered development of members. The Company will continue

to upgrade "Ping An Family Doctors", and proactively reach and serve users from F-end and B-end payers, to improve users' awareness and experience. The Company will also work with Ping An Group to step up home-based senior care business in an effort to further integrate health and senior care with commercial insurance. In the future, as user habits get formed, the Company will take more actions to boost F2C/B2C conversion to forge a second growth curve. In its pursuit of a broader service network and better service quality, the Company will consolidate its advantages in the "online, in-store, and home/company-delivered" service network to strengthen its bargaining power derived from the upscaling of services. By doing so, the Company will develop a broader, high-quality, cost-effective health and senior care service network. In addition, Ping An Health will improve resource allocation and organizational efficiency through further optimization of operational processes and progressive implementation of digitization and AI technology.

Going forward, Ping An Health will keep striving to create sustained long-term value for users, shareholders, and the society. The Company will provide users with high-quality health and senior care services, deliver steady returns to shareholders, and unswervingly support the Digital China and the Healthy China initiatives.

## **Revenue and Gross Profit by Segment**

|                       | Six months er<br>2024<br>RMB'000 | nded 30 June<br>2023*<br>RMB'000 | Year-on-year change |  |  |
|-----------------------|----------------------------------|----------------------------------|---------------------|--|--|
| Revenue:              |                                  |                                  |                     |  |  |
| Medical services      | 1,062,743                        | 1,031,559                        | +3.0%               |  |  |
| Health services       | 983,392                          | 1,175,093                        | -16.3%              |  |  |
| Senior care services  | 47,314                           | 15,525                           | +204.8%             |  |  |
| Total of revenue      | 2,093,449                        | 2,222,177                        | -5.8%               |  |  |
| Gross profit:         |                                  |                                  |                     |  |  |
| Medical services      | 422,236                          | 443,888                          | -4.9%               |  |  |
| Health services       | 243,573                          | 270,957                          | -10.1%              |  |  |
| Senior care services  | 7,989                            | 517                              | +1,445.3%           |  |  |
| Total of gross profit | 673,798                          | 715,362                          | -5.8%               |  |  |
| Gross margin:         |                                  |                                  |                     |  |  |
| Medical services      | 39.7%                            | 43.0%                            | -3.3 pps            |  |  |
| Health services       | 24.8%                            | 23.1%                            | +1.7 pps            |  |  |
| Senior care services  | 16.9%                            | 3.3%                             | +13.6 pps           |  |  |
| Total of gross margin | 32.2%                            | 32.2%                            | -                   |  |  |

In the context of Ping An Group's consistent pursuit of the "integrated finance + health and senior care" strategy, as a flagship in Ping An Group's health and senior care ecosystem, Ping An Health is the integrator and provider of senior care services. The senior care services business is an important part of the Company's strategic layout, which contributes to a new business growth. The Company disclosed its revenue by segment (including three segments, namely medical services, health services and senior care services) to better reflect the Company's business strategy. Segment information in the same period of 2023 has been restated.

#### **Medical Services:**

During the Reporting Period, revenue from medical services recorded RMB1,062.7 million, representing an increase of 3% from RMB1,031.6 million in the same period of 2023. The slight increase in revenue from medical services was mainly because Ping An Health continuously deepened synergy with Ping An Group's integrated finance business for the purpose of diversifying medical services centered on family doctors, including medical consultation, chronic disease management and medical visit assistance.

During the Reporting Period, gross margin of medical services recorded 39.7%, representing a slight decrease of 3.3 pps year on year. This was mainly due to structural changes in the medical business.

|              | Six months ended 30 June |           |                     |
|--------------|--------------------------|-----------|---------------------|
|              | 2024                     | 2023*     | Year-on-year change |
|              | RMB'000                  | RMB'000   |                     |
| Revenue      | 1,062,743                | 1,031,559 | +3.0%               |
| Gross profit | 422,236                  | 443,888   | -4.9%               |
| Gross margin | 39.7%                    | 43.0%     | -3.3 pps            |

#### **Health Services:**

During the Reporting Period, revenue from health services recorded RMB983.4 million, representing a decrease of 16.3% from RMB1,175.1 million in the same period of 2023. The decrease was mainly attributable to ongoing realignment of the business of some physical products that is less correlated with the managed care strategy and has low profitability, and contract fulfillment concentrated due to some one-off factor in the first half of 2023.

During the Reporting Period, gross margin of health services recorded 24.8%, with a steady increase of 1.7 pps. This was mainly due to the declined proportion of revenue from business with low profitability.

|              | Six months ended 30 June |           |                     |
|--------------|--------------------------|-----------|---------------------|
|              | 2024                     | 2023*     | Year-on-year change |
|              | RMB'000                  | RMB'000   |                     |
| Revenue      | 983,392                  | 1,175,093 | -16.3%              |
| Gross profit | 243,573                  | 270,957   | -10.1%              |
| Gross margin | 24.8%                    | 23.1%     | +1.7 pps            |

#### **Senior Care Services:**

During the Reporting Period, Ping An Health continued to promote and deepen the in-depth integration with Ping An Group's commercial insurance, and actively deployed the senior care services business centered on senior care concierges. The revenue from senior care services for the first half of 2024 recorded RMB47.3 million, compared to RMB15.5 million for the same period in 2023.

During the Reporting Period, the gross profit margin of the senior care services recorded 16.9%, representing a year-on-year increase of 13.6 pps. This was mainly due to the Company's intensified efforts to develop a comprehensive "3-in-1" senior care concierge system integrating smart concierges, daily life concierges, and doctor concierges, covering multi-scenario service experience, thus comprehensively improving the gross profit margin.

|              | Six months ended 30 June |         |                     |
|--------------|--------------------------|---------|---------------------|
|              | 2024                     | 2023*   | Year-on-year change |
|              | RMB'000                  | RMB'000 |                     |
| Revenue      | 47,314                   | 15,525  | +204.8%             |
| Gross profit | 7,989                    | 517     | +1,445.3%           |
| Gross margin | 16.9%                    | 3.3%    | +13.6 pps           |

## **Selling and Marketing Expenses**

Selling and marketing expenses amounted to RMB366.7 million in the first half of 2024, representing a decrease of 18.6% from RMB450.3 million in the first half of 2023. The decrease was mainly due to continuously strengthened input-output management and enhanced resource allocation efficiency.

## **Administrative Expenses**

Administrative expenses amounted to RMB394.6 million in the first half of 2024, representing a decrease of 47.8% from RMB756.7 million in the first half of 2023. The decrease was mainly attributable to the decrease in manpower and related expenses as a result of continuous optimization in staffing efficiency.

#### Other Income

Other income amounted to RMB18.3 million in the first half of 2024, representing a decrease of 66.9% from RMB55.3 million in the first half of 2023, which was mainly attributable to the decrease in government grants during the period.

#### Other Gains - Net

Other net gains amounted to RMB27.7 million in the first half of 2024, representing a decrease of RMB51.6 million from RMB79.3 million in the first half of 2023, which was mainly attributable to the change in impairment amount of receivables.

#### Finance Income - Net

Net finance income amounted to RMB102.4 million in the first half of 2024, representing a decrease of 11.1% from RMB115.2 million in the first half of 2023, which was mainly attributable to a decrease in interest income of the Company.

## Net Profit/Loss for the Period and the Non-IFRS Measure: Adjusted **Net Profit/Loss**

Our net profit for the first half of 2024 amounted to RMB60.6 million, compared with net loss of RMB244.9 million recorded in the first half of 2023. To supplement our consolidated financial information presented in accordance with IFRS, we also adopted the "adjusted net profit/loss" which is not a required standard under IFRS or which is presented not in accordance with IFRS requirements as an additional financial measure. For the purpose of this interim report and future interim reports, the "adjusted net profit/loss" may be used in exchange with the "net profit/loss not under GAAP". We believe that this additional financial measure is useful for comparing our operating performance between different periods and different companies by eliminating the potential impact of items which, in the opinion of our management, are not indicative of our operating performance. We also believe that the additional measure can provide investors and other individuals with meaningful information, allowing them to understand and assess our consolidated operating results in the same way as our management. However, the "adjusted net profit/loss" presented by us may not necessarily be comparable with the similar measures presented by other companies. Such non-IFRS measure has a limitation as an analytical tool. Thus, a view should not be held that it is independent from or can replace the analysis of our operating results or financial position presented in accordance with IFRS. After excluding the impact of share-based payments and net foreign exchange (gains)/losses, the adjusted net profit in the first half of 2024 amounted to RMB89.7 million, compared with the adjusted net loss of RMB249.3 million in the first half of 2023. The following table sets forth the adjusted net profit/loss for the six months ended 30 June 2024 and 2023 as the most directly comparable financial measure (namely, net profit/loss for the period) calculated and presented in accordance with IFRS:

|  | Six months e | Six months ended 30 June |  |
|--|--------------|--------------------------|--|
|  | 2024         | 2023                     |  |
|  | RMB'000      | RMB'000                  |  |
| Net profit/(loss) for the period         | 60,629       | (244,867)                |  |
| Excluding:                               |              |                          |  |
| Share-based payments                     | 29,833       | 5,912                    |  |
| Net foreign exchange (gains)/losses      | (723)        | 1,899                    |  |
| Net gains on disposal of a joint venture | -            | (12,211)                 |  |
| Adjusted net profit/(loss)               | 89,739       | (249,267)                |  |

## **Liquidity and Financial Resources**

Our cash and other liquid financial resources as of 30 June 2024 and 31 December 2023 were as follows:

|     | 30 June<br>2024<br>RMB'000 | 31 December<br>2023<br>RMB'000 |
|-----|----------------------------|--------------------------------|
| RMB | 2,922,821                  | 1,776,663                      |
| USD | 63,351                     | 65,902                         |
| HKD | 22,483                     | 23,946                         |
|     | 3,008,655                  | 1,866,511                      |

Cash and cash equivalents include cash in hand and at banks, bank deposits, and other short-term highly liquid deposits with original maturities of three months or less. Our cash and cash equivalents are mostly denominated in RMB.

As of 30 June 2024, our total available funds were RMB12,644.8 million, including cash and cash equivalents of RMB3,008.7 million, restricted cash of RMB75.1 million, term deposits of RMB3,622.1 million, and financial assets for wealth management of RMB5,938.9 million. The financial assets for wealth management, purchased mainly from Ping An Bank, Ping An Wealth Management and others, have effectively improved the yields and liquidity of the Company's idle funds.

Cash flows for the six months ended 30 June 2024 and six months ended 30 June 2023 were as follows:

|  | Unaudited<br>Six months ended 30 June |                                 |
|--|---------------------------------------|---------------------------------|
|  | 2024<br>RMB'000 RME                   |                                 |
| Net cash used in operating activities  Net cash generated from investing activities  Net cash used in financing activities | (135,007)<br>1,295,072<br>(18,740)    | (67,262)<br>984,553<br>(28,733) |
| Net increase in cash and cash equivalents  | 1,141,325                             | 888,558                         |
| Cash and cash equivalents at the beginning of the period Effects of exchange rate changes on cash and cash equivalents     | 1,866,511<br>819                      | 3,700,689<br>6,011              |
| Cash and cash equivalents at the end of the period   | 3,008,655                             | 4,595,258                       |

Net cash generated from investing activities mainly included proceeds of RMB9,135.1 million from redemption of wealth management products and term deposits, and subscription of wealth management products and term deposits of RMB7,830.1 million.

## **Treasury Policy**

Our cash arises almost exclusively from equity funding. Such cash can only be invested in relatively liquid and low-risk instruments such as bank deposits or money market instruments. The primary objective of our investments is to generate finance income at a yield higher than the interest rate of current bank deposits, and to maintain liquidity.

## **Capital Expenditure**

|  | Six months ended 30 June |                 |
|--|--------------------------|-----------------|
|  | 2024<br>RMB'000          | 2023<br>RMB'000 |
| Purchase of property, plant and equipment, intangible assets and other |                          |                 |
| assets   | 10,536                   | 17,138          |

Our capital expenditures primarily comprised the expenditure for the purchase of property, plant and equipment (mainly office and telecommunication equipment) as well as intangible assets (mainly software).

## Foreign Exchange Risk

For the six months ended 30 June 2024, we mainly operated our businesses in China with most of the transactions settled in RMB, the functional currency of our Company. Foreign exchange risk is the risk of incurring losses due to changes in foreign exchange rates. Fluctuations in the exchange rates between RMB and other currencies that we use to conduct our business operations may affect our financial position and operating results. The foreign exchange risk assumed by us primarily arises from movements in the USD/RMB exchange rates. Considering the foreign exchange risks potentially brought by the fluctuations in the exchange rates, the Company would adopt financial instruments in response to the fluctuations in the exchange rates at any time.

## **Pledge of Assets**

As of 30 June 2024, none of our assets were pledged.

#### **Provisions**

 $For the provisions, please \ refer to \ note \ 27 \ "Provisions" \ to \ the interim \ condensed \ consolidated \ financial \ information.$ 

#### **Dividend**

For the six months ended 30 June 2024, we did not pay or declare any dividend.

## **Bank Loans and Other Borrowings**

As at 30 June 2024, except for the borrowings with a fixed rate of RMB10,500,000 obtained by Pingan Yingjian, a subsidiary of the Company, from its shareholder, Yingjian Enterprise Management Consulting, we did not have any outstanding loans. As at 30 June 2024, the Group's gearing ratio was 17.47%, which was calculated by dividing the Group's total liabilities by its total assets as at 30 June 2024.

## Significant Investments Held

As at 30 June 2024, we did not hold any material investments with a value of 5% or more of the Group's total assets.

## **Material Investment and Future Plans of Capital Assets**

As of 30 June 2024, we did not have any material investment and other plans of capital assets.

### Material Acquisitions and Disposals of Subsidiaries, Associates and Joint ventures

For the six months ended 30 June 2024, we did not carry out any material acquisitions and disposals of subsidiaries, associates and joint ventures.

## **Employee and Remuneration Policy**

The Group had a total of 1,446 employees as of 30 June 2024, the majority of whom were based in various cities in the PRC, including Shanghai, Guangzhou, Shenzhen, Hefei, Qingdao and Beijing. The Group has established a remuneration system of "cash salary + benefit + long-term incentive." Remuneration is determined with reference to market conditions and individual employees' performance, qualifications and experience. In line with the performance of the Company and individual employees, a competitive remuneration package is offered to retain employees, including salaries, discretionary bonuses and benefit plans. Employees of the Company are eligible participants of the Pre-IPO employee share option scheme, details of which are set out in the Prospectus. In addition to on-the-job training, we have also adopted training policies to provide a wide range of in-house and external trainings for employees. During the Reporting Period, the relationship between the Company and our employees was always stable. We did not experience any strikes or other labor disputes which materially affected our business activities.

## Directors' and Chief Executives' Interests and Short Positions in the **Shares, Underlying Shares and Debentures**

As at 30 June 2024, the interests and short positions of the Directors and chief executives of the Company in the Shares, underlying Shares and debentures of the Company or its associated corporations, within the meaning of Part XV of the SFO, which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he/she was taken or deemed to have taken under such provisions of the SFO), or were recorded in the register required to be maintained by the Company under section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code, were as follows:

#### Long positions/short positions in the Shares of the Company

| Name of Director          | Nature of interest | Number of Shares held | Long positions/ short positions | Approximate percentage of interest in the Company <sup>(1)</sup> |
|---------------------------|--------------------|-----------------------|---------------------------------|--|
| Mr. Dou Li <sup>(2)</sup> | Beneficial owner   | 300,000               | Long positions                  | 0.03%  |
| Mr. Jun Wu <sup>(3)</sup> | Beneficial owner   | 328,345               | Long positions                  | 0.03%  |

#### Notes:

- (1) The calculation is based on the total number of Shares in issue of 1.118.812.900 Shares as of 30 June 2024.
- (2) As of 30 June 2024, Mr. Dou Li was entitled to 300,000 Shares pursuant to the Employee Incentive Scheme, where no Share was held upon exercise of EIS Options under the Employee Incentive Scheme.
- (3) As of 30 June 2024, Mr. Jun Wu was entitled to 328,345 Shares pursuant to the Employee Incentive Scheme, where no Share was held upon exercise of EIS Options under the Employee Incentive Scheme.

Save as disclosed above, as of 30 June 2024, so far as known to the Directors, none of the Directors or chief executives of the Company had or was deemed to have interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations, within the meaning of Part XV of the SFO, which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have taken under such provisions of the SFO), or were recorded in the register required to be maintained by the Company under section 352 of the SFO, or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

## **Substantial Shareholders' Interests and Short Positions in the Shares** and Underlying Shares of the Company

As of 30 June 2024, so far as known to the Directors, the following persons (other than the Directors or chief executives of the Company) had interests or short positions in the Shares or underlying Shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under section 336 of the SFO, or were, directly or indirectly, interested in 5% or more of the Shares of the Company:

#### Long positions/short positions in the Shares of the Company

| Name of Shareholder                                   | Nature of interest                  | Number of<br>Shares held | Long positions/<br>short positions | Approximate percentage of interest in the Company <sup>(1)</sup> |
|---|-------------------------------------|--------------------------|------------------------------------|--|
| Glorious Peace <sup>(2)</sup>                         | Beneficial owner                    | 441,000,000              | Long positions                     | 39.41%   |
| An Ke Technology Company<br>Limited <sup>(2)</sup>    | Interest in controlled corporations | 441,000,000              | Long positions                     | 39.41%   |
| Ping An <sup>(2)</sup>                                | Interest in controlled corporations | 441,000,000              | Long positions                     | 39.41%   |
| Hopson Development<br>Holdings Limited <sup>(3)</sup> | Interest in controlled corporations | 97,726,100               | Long positions                     | 8.73%  |
| Sounda Properties Limited <sup>(3)</sup>              | Interest in controlled corporations | 97,726,100               | Long positions                     | 8.78%  |
|   | Beneficial owner                    | 504,700                  | Long positions                     |  |
| Mang Yee Chu <sup>(3)</sup>                           | Interest in controlled corporations | 98,230,800               | Long positions                     | 8.78%  |

#### Notes:

- (1) The calculation is based on the total number of Shares in issue of 1,118,812,900 Shares as of 30 June 2024.
- (2) As of 30 June 2024, Glorious Peace directly held a total of 441,000,000 Shares. Glorious Peace was wholly-owned by An Ke Technology Company Limited, which in turn was wholly-owned by Ping An. As such, each of Ping An and An Ke Technology Company Limited was deemed to be interested in the Shares held by Glorious Peace.
- (3) According to the form of disclosure of interest (the "form of disclosure of interest") dated 5 February 2024 filed by Hopson Development Holdings Limited ("Hopson Development") in relation to the relevant event on 31 January 2024, Hopson Development, through a series of corporations controlled by it, was interested in an aggregate of 97,726,100 Shares of the Company. According to the form of disclosure of interest filed by Sounda Properties Limited ("Sounda") dated 5 February 2024 in relation to the relevant event on 31 January 2024, Sounda was deemed to hold 98,230,800 Shares, comprising 97,726,100 Shares indirectly held through Hopson Development which was controlled by Sounda, and 504,700 Shares directly held by Sounda. According to the form of disclosure of interest filed by Mr. Mang Yee Chu dated 5 February 2024 in relation to the relevant event on 31 January 2024, Sounda was wholly-owned by Mr. Mang Yee Chu. As such, Mr. Mang Yee Chu was deemed to be interested in the interest held by Sounda.
- (4) Pursuant to section 336 of the SFO, the Shareholders are required to file forms of disclosure of interests when certain criteria are fulfilled and the full details of the requirements are available on the Stock Exchange's official website. When a Shareholder's shareholding in the Company changes, it is not necessary to notify the Company and the Stock Exchange unless certain criteria are fulfilled. Therefore, substantial Shareholders' latest shareholdings in the Company may be different to the shareholdings filed with the Company and the Stock Exchange. The above statements of substantial Shareholders' interests are prepared based on the information in the forms of disclosure of interest for the relevant events as of 30 June 2024 filed by substantial Shareholders. The Company may not have sufficient information on the breakdown of the relevant interests and cannot verify the accuracy of information in the forms of disclosure of interest.

Save as disclosed above, as of 30 June 2024, the Directors were not aware of any person (other than the Directors or chief executives of the Company) who had interests or short positions in the Shares or underlying Shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or were recorded in the register required to be kept by the Company under section 336 of the SFO, or who was, directly or indirectly, interested in 5% or more of the Shares of the Company.

## **Employee Incentive Scheme**

The Employee Incentive Scheme was approved by the Board on 26 December 2014 and amended by the Board from time to time. The purpose of the Employee Incentive Scheme is to attract and retain talents, and promote the long-term sustainable development of the Company and related entities, so as to realize the maximization of value for Shareholders, and achieve mutual benefits of the Shareholders, the Company and the employees.

The EIS Shares had been issued, which were directly held by Le An Xin. Given the EIS Shares had already been issued, there will not be any dilution effect to the proportion of shareholding upon the exercise of the options granted under the EIS. In addition, the grant of the EIS Options by the Company or transfer upon vesting of the EIS Options of any of the EIS Shares pursuant to the Employee Incentive Scheme by any trustee or trust holding entities to a connected person of the Company should not be subject to the requirements of Chapter 14A of the Listing Rules. As of 30 June 2024, the aggregate number of outstanding Shares underlying the EIS Options as granted by the Company under the Employee Incentive Scheme was 10,985,645, representing 0.98% of the Company's issued share capital. All such Shares underlying the EIS Options have been issued.

The following table shows details of the options granted under the EIS for the six months ended 30 June 2024:

| Name                                       | Position  | Date of grant <sup>1</sup> | Number<br>of grants<br>(Shares) | Vesting period <sup>2</sup>           | Exercise<br>price<br>(HK\$/share) | Outstanding<br>as of<br>1 January<br>2024<br>(Shares) | Exercised<br>during the<br>Reporting<br>Period <sup>3</sup><br>(Shares) | Cancelled/<br>Lapsed<br>during the<br>Reporting<br>Period<br>(Shares) | Outstanding<br>as of<br>30 June<br>2024<br>(Shares) |
|--|---|----------------------------|---------------------------------|---------------------------------------|-----------------------------------|---|---|---|---|
| Mr. Dou Li                                 | Executive Director, chairman of the Board and chief executive officer | 1 December 2023            | 300,000                         | 1 December 2024 to<br>1 December 2027 | -                                 | 300,000   | -   | -   | 300,000   |
| Mr. Jun Wu                                 | Executive Director and president                                      | 26 October 2021            | 300,000                         | 26 October 2022 to<br>26 October 2025 | -                                 | 228,345   | -   | -   | 228,345   |
|  |   | 23 October 2022            | 100,000                         | 23 October 2023 to<br>23 October 2026 | -                                 | 100,000   | -   | -   | 100,000   |
| Five highest paid individuals in aggregate |   | 21 October 2020            | 140,000                         | 21 October 2021 to<br>21 October 2024 | -                                 | 71,561  | -   | -   | 71,561  |
|  |   | 26 October 2021            | 300,000                         | 26 October 2022 to<br>26 October 2025 | -                                 | 228,345   | -   | -   | 228,345   |
|  |   | 29 January 2022            | 188,000                         | 29 January 2023 to<br>29 January 2026 | -                                 | 143,095   | -   | -   | 143,095   |
|  |   | 15 March 2022              | 250,000                         | 15 March 2023 to<br>15 March 2026     | -                                 | 250,000   | -   | -   | 250,000   |
|  |   | 23 October 2022            | 200,000                         | 23 October 2023 to<br>23 October 2026 | -                                 | 200,000   | -   | -   | 200,000   |

| Name           | Position | Date of grant <sup>1</sup> | Number<br>of grants<br>(Shares) | Vesting period <sup>2</sup>             | Exercise<br>price<br>(HK\$/share) | Outstanding<br>as of<br>1 January<br>2024<br>(Shares) | Exercised<br>during the<br>Reporting<br>Period <sup>3</sup><br>(Shares) | Cancelled/<br>Lapsed<br>during the<br>Reporting<br>Period<br>(Shares) | Outstanding<br>as of<br>30 June<br>2024<br>(Shares) |
|----------------|----------|----------------------------|---------------------------------|---|-----------------------------------|---|---|---|---|
|                |          | 19 December 2022           | 80,000                          | 19 December 2023 to<br>19 December 2026 | -                                 | 80,000  | -   | -   | 80,000  |
|                |          | 1 December 2023            | 300,000                         | 1 December 2024 to<br>1 December 2027   | -                                 | 300,000   | -   | -   | 300,000   |
| Other grantees |          | 31 December 2014           | 4,917,500                       | 31 December 2015 to 31 December 2018    | 0.63                              | -   | -   | -   | -   |
|                |          | 31 March 2015              | 280,000                         | 31 March 2016 to<br>31 March 2019       | 0.63                              | 27,500  | -   | -   | 27,500  |
|                |          | 30 June 2015               | 148,000                         | 30 June 2016 to<br>30 June 2019         | 0.63                              | -   | -   | -   | -   |
|                |          | 1 October 2015             | 11,534,500                      | 1 October 2016 to<br>1 October 2019     | 0.91                              | 57,674  | -   | -   | 57,674  |
|                |          | 25 February 2016           | 3,923,000                       | 25 February 2017 to<br>25 February 2020 | 5.95                              | 105,300   | 7,200   | -   | 98,100  |
|                |          | 31 March 2017              | 16,475,800                      | 31 March 2018 to<br>31 March 2021       | 26.47                             | 875,979   | -   | -   | 875,979   |
|                |          | 30 November 2017           | 14,287,098                      | 30 November 2018 to<br>30 November 2021 | 37.84                             | 1,237,702   | -   | 1,685   | 1,236,017   |
|                |          | 31 December 2017           | 840,000                         | 31 December 2018 to 31 December 2021    | 37.84                             | -   | -   | -   | -   |
|                |          | 28 February 2019           | 3,867,694                       | 28 February 2020 to<br>28 February 2023 | 0-36.21                           | 719,631   | 9,829   | 1,440   | 708,362   |
|                |          | 31 May 2019                | 188,335                         | 31 May 2020 to<br>31 May 2023           | -                                 | 8,459   | -   | -   | 8,459   |
|                |          | 31 August 2019             | 110,713                         | 31 August 2020 to<br>31 August 2023     | -                                 | 19,038  | -   | -   | 19,038  |
|                |          | 8 September 2019           | 100,000                         | 8 September 2020 to<br>8 September 2023 | -                                 | 24,865  | -   | -   | 24,865  |
|                |          | 30 November 2019           | 25,575                          | 30 November 2020 to<br>30 November 2023 | -                                 | -   | -   | -   | -   |
|                |          | 21 October 2020            | 1,812,100                       | 21 October 2021 to<br>21 October 2024   | -                                 | 600,496   | 10,046  | 24,999  | 565,451   |
|                |          | 31 December 2020           | 166,600                         | 31 December 2021 to 31 December 2024    | -                                 | 35,854  | 6,740   | 6,783   | 22,331  |
|                |          | 11 January 2021            | 300,000                         | 21 October 2021 to<br>21 October 2024   | -                                 | 153,345   | -   | -   | 153,345   |
|                |          | 31 May 2021                | 260,000                         | 31 May 2022 to<br>31 May 2025           | -                                 | 212,500   | -   | -   | 212,500   |
|                |          | 24 August 2021             | 3,284,700                       | 24 August 2022 to<br>24 August 2025     | -                                 | 184,904   | -   | -   | 184,904   |
|                |          | 26 October 2021            | 248,600                         | 26 October 2022 to<br>26 October 2025   | -                                 | 10,656  | -   | -   | 10,656  |

| Name   | Position | Date of grant <sup>1</sup> | Number<br>of grants<br>(Shares) | Vesting period <sup>2</sup>             | Exercise<br>price<br>(HK\$/share) | Outstanding<br>as of<br>1 January<br>2024<br>(Shares) | Exercised<br>during the<br>Reporting<br>Period <sup>3</sup><br>(Shares) | Cancelled/<br>Lapsed<br>during the<br>Reporting<br>Period<br>(Shares) | Outstanding<br>as of<br>30 June<br>2024<br>(Shares) |
|--------|----------|----------------------------|---------------------------------|---|-----------------------------------|---|---|---|---|
|        |          | 29 January 2022            | 3,041,200                       | 29 January 2023 to<br>29 January 2026   | -                                 | 1,777,494   | 13,556  | 88,650  | 1,675,288   |
|        |          | 20 May 2022                | 230,000                         | 20 May 2023 to<br>20 May 2026           | -                                 | 30,000  | -   | -   | 30,000  |
|        |          | 26 July 2022               | 25,000                          | 26 July 2023 to<br>26 July 2026         | -                                 | 6,250   | -   | -   | 6,250   |
|        |          | 23 October 2022            | 375,000                         | 23 October 2023 to<br>23 October 2026   | -                                 | 243,750   | -   | -   | 243,750   |
|        |          | 19 December 2022           | 5,432,000                       | 19 December 2023 to<br>19 December 2026 | -                                 | 4,046,750   | -   | 494,575   | 3,552,175   |
| Total⁴ |          |                            | 73,331,4155                     | 1                                       |                                   | 11,651,148  | 47,371  | 618,132   | 10,985,645  |

#### Notes:

- The performance of the EIS Options granted during the year depended on the degree of satisfaction of specific performance, including fulfillment of the key performance indicators by the Group as a whole and the grantees;
- 2 The EIS Options may be exercised once vested, subject to a period of 10 years commencing from the date of grant;
- The weighted average closing price immediately before the date on which the EIS Options were exercised was HK\$11.23/share;
- For the avoidance of double counting, it represents the sum of the options of the five highest paid individuals (including the Directors Mr. Dou Li and Mr. Jun Wu) and other grantees;
- The number of shares granted was the number of shares originally granted, including the number of shares canceled/lapsed and

## Purchase, Sale or Redemption of the Company's Listed Securities

For the six months ended 30 June 2024, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including sales of treasury shares).

## **Changes of Directors and Chief Executives and Their Information**

During the Reporting Period, pursuant to the disclosure requirement under Rule 13.51B(1) of the Listing Rules, the changes in personal information of the Directors are as follows:

1. Mr. Michael Guo, a non-executive Director, has served as a director of Ping An Life Insurance Company of China, Ltd. (中國平安人壽保險股份有限公司) since 15 May 2024.

Save as disclosed above, as of the date of this interim report, there was no other information required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

## **Audit and Risk Management Committee**

The Company has established an Audit and Risk Management Committee in compliance with the Corporate Governance Code. The primary duties of the Audit and Risk Management Committee are to review and supervise the financial reporting process and internal control system of the Group, review the financial information of the Group and consider issues relating to the external auditors and their appointment.

The Audit and Risk Management Committee comprises two independent non-executive Directors, namely, Mr. Yunwei Tang and Mr. Tianyong Guo and one non-executive Director, namely, Ms. Fangfang Cai. Mr. Yunwei Tang, being the chairman of the Audit and Risk Management Committee, is appropriately qualified as required.

The Audit and Risk Management Committee has reviewed the unaudited interim financial accounts of the Group for the six months ended 30 June 2024. The Audit and Risk Management Committee has also discussed with management of the Company the accounting policies and practices and internal controls adopted by the Company. Based on the above review and discussion with management, the Audit and Risk Management Committee is satisfied that the unaudited interim financial information of the Group has been prepared in accordance with the applicable accounting standards.

### Compliance with the Code of Conduct Regarding Directors' Securities **Transactions**

The Company has adopted the Model Code as the code of conduct regarding Directors' dealings in the securities of the Company. Having made specific enquiry to all the Directors, all the Directors confirmed that they have complied with the required standards set out in the Model Code for the six months ended 30 June 2024.

The Board has also established written guidelines to regulate all dealings by informed persons who are likely to be in possession of inside information in respect of the Company's securities and unpublished information as referred to in code provision C.1.3 of the Corporate Governance Code.

## **Compliance with the Corporate Governance Code**

The Directors confirmed that the Company had complied with all the applicable code provisions as set out in the Corporate Governance Code for the six months ended 30 June 2024, except for code provision C.2.1.

Code provision C.2.1 of the Corporate Governance Code provides that the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Mr. Dou Li concurrently holds the positions of both the chairman and the chief executive officer of the Company. However, the Board is of the opinion that the Company has built up a structure of the Board and has developed a very structured and strict operation system and a set of procedural rules for the meeting of the Board. The chairman does not have any special power different from that of other Directors of the Company in relation to the decision-making process of the Company. Also, in the day-to-day operation of the Company, the Company has put in place an integrated system and structure. Decisions on all material matters will be subject to complete and stringent deliberation and decision-making procedures in order to ensure that the chief executive officer can perform his duties in a compliant and effective manner. At the same time, based on the actual situation of the Company and considering Mr. Dou Li's professional competence and extensive experience in various fields such as medicine, fast-moving consumer goods, insurance and senior care, vesting the roles of both chairman and chief executive officer in the same person is beneficial to the implementation and execution of the strategies and business of the Company. Based on the above reasons, the Board is of the opinion that the Company's management structure is superior to the arrangements under the code provision and is able to provide the Company with efficient management and at the same time, protect all Shareholders' rights and interests to the greatest extent.

Therefore, the Company does not currently intend to separate the roles of the chairman and the chief executive officer.

#### **Use of Proceeds**

#### Use of Net Proceeds from the Listing

The Shares of the Company were listed on the Main Board of the Stock Exchange on the Listing Date with net proceeds received by the Company from the global offering in the amount of approximately HK\$8,564.0 million after deducting underwriting commissions and all related expenses. The proceeds from the Listing were used and are proposed to be used according to the intentions previously disclosed by the Company. The following table sets forth the Group's intended timetable for use of proceeds from the Listing as of 30 June 2024.

| Inten | ded use of net proceeds  | Allocation<br>of net<br>proceeds | Amount of<br>net proceeds<br>utilized for<br>the six<br>months ended<br>30 June 2024<br>(HK\$ in<br>million) | Balance of<br>net proceeds<br>unutilized as of<br>30 June 2024 | Intended timetable<br>for use of the<br>unutilized net proceeds |
|-------|--|----------------------------------|--|--|---|
| (i)   | Business expansion   | 3,425.6                          | 396.8  | 404.0  | Before 31 December 2024   |
| (ii)  | Funding our potential investments, acquisitions of domestic companies and the strategic alliances with domestic companies as well as our overseas expansion plan | 2,569.2                          | -  | 1,537.9  | Before 31 December 2025   |
| (iii) | Research and development   | 1,712.8                          | -  | -  | Before 31 December 2026   |
| (iv)  | Working capital and general corporate purposes   | 856.4                            | -  | -  | N/A   |

#### **Use of Net Proceeds from the Placing**

References are made to the announcements of the Company dated 30 September 2020 and 9 October 2020 (the "Announcements"), and for the purposes of seizing market opportunities, solidifying the Company's leading position in the industry and laying a solid foundation for business expansion, on 30 September 2020, the Company entered into a placing agreement with the placing agents in relation to the placing of an aggregate of 80,000,000 new Shares with the aggregate nominal value of USD400, at a placing price of HK\$98.20 per placing share on the terms and conditions set out in the placing agreement. The market price of the placing shares was HK\$99.25 on the date of the placing agreement.

On 9 October 2020, the Company completed the placing of 80,000,000 ordinary shares to no less than six placees who are Independent Third Parties of the Company at a price of HK\$98.20 per placing share with net proceeds received by the Company from the placing in the amount of approximately HK\$7,828.0 million after deducting the commission, incentive fee and expense, representing a net issue price of approximately HK\$97.85 per placing share. The proceeds from the placing are proposed to be used according to the intentions previously disclosed by the Company. The following table sets forth the Group's intended timetable for use of proceeds from the placing as of 30 June 2024.

| Intended use of net proceeds                    | Allocation<br>of net<br>proceeds |   | Balance of net proceeds unutilized as of | Intended timetable<br>for use of the<br>unutilized net proceeds |
|---|----------------------------------|---|--|---|
| Further developing core businesses of the Group | 7,828.0                          | - | 7,828.0                                  | Before 31 December 2030   |

## **Report on Review of Interim Financial Information**

#### To the Board of Directors of Ping An Healthcare and Technology Company Limited

(incorporated in the Cayman Islands with limited liability)

#### Introduction

We have reviewed the interim financial information set out on pages 33 to 72, which comprises the interim condensed consolidated statement of financial position of Ping An Healthcare and Technology Company Limited (the "Company") and its subsidiaries (together, the "Group") as at 30 June 2024 and the interim condensed consolidated income statement, the interim condensed consolidated statement of comprehensive income, the interim condensed consolidated statement of changes in equity and the interim condensed consolidated statement of cash flows for the six-month period then ended, and selected explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 "Interim Financial Reporting". The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with International Accounting Standard 34 "Interim Financial Reporting". Our responsibility is to express a conclusion on this interim financial information based on our review and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

## **Scope of Review**

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

#### Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information of the Group is not prepared, in all material respects, in accordance with International Accounting Standard 34 "Interim Financial Reporting".

#### **PricewaterhouseCoopers**

Certified Public Accountants

Hong Kong, 20 August 2024

## **Interim Condensed Consolidated Income Statement**

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

|  |      | Six months ende | hs ended 30 June |  |  |
|--|------|-----------------|------------------|--|--|
|  | Note | 2024            | 2023             |  |  |
|  |      | (unaudited)     | (unaudited)      |  |  |
| Revenue  | 6    | 2,093,449       | 2,222,177        |  |  |
| Cost of sales                                    | 6,7  | (1,419,651)     | (1,506,815)      |  |  |
| Gross profit                                     |      | 673,798         | 715,362          |  |  |
| Selling and marketing expenses                   | 7    | (366,722)       | (450,346)        |  |  |
| Administrative expenses                          | 7    | (394,613)       | (756,671)        |  |  |
| Other income                                     | 8    | 18,284          | 55,274           |  |  |
| Other gains - net                                | 9    | 27,737          | 79,291           |  |  |
| Operating loss                                   |      | (41,516)        | (357,090)        |  |  |
| Finance income                                   | 10   | 103,977         | 119,285          |  |  |
| Finance costs                                    | 10   | (1,541)         | (4,043)          |  |  |
| Finance income - net                             | 10   | 102,436         | 115,242          |  |  |
| Share of losses of associates and joint ventures |      | (268)           | (2,415)          |  |  |
| Profit/(Loss) before income tax                  |      | 60,652          | (244,263)        |  |  |
| Income tax expense                               | 11   | (23)            | (604)            |  |  |
| Profit/(Loss) for the period                     |      | 60,629          | (244,867)        |  |  |
| Profit/(Loss) attributable to:                   |      |                 |                  |  |  |
| - Owners of the Company                          |      | 56,648          | (244,618)        |  |  |
| - Non-controlling interests                      |      | 3,981           | (249)            |  |  |
|  |      | 60,629          | (244,867)        |  |  |
| Earnings/(Loss) per share attributable           |      |                 |                  |  |  |
| to owners of the Company                         |      |                 |                  |  |  |
| - Basic (RMB yuan)                               | 12   | 0.05            | (0.23)           |  |  |
| - Diluted (RMB yuan)                             | 12   | 0.05            | (0.23)           |  |  |

The accompanying notes form an integral part of the interim condensed consolidated financial information.

# **Interim Condensed Consolidated Statement of Comprehensive Income**

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

|   |      | Six months end      | ed 30 June          |
|---|------|---------------------|---------------------|
|   | Note | 2024<br>(unaudited) | 2023<br>(unaudited) |
| Profit/(Loss) for the period                          |      | 60,629              | (244,867)           |
| Other comprehensive income                            |      |                     |                     |
| Items that may be reclassified to profit or loss      |      |                     |                     |
| Exchange differences on translation of                |      |                     |                     |
| foreign operations                                    |      | 8,392               | 52,139              |
| Other comprehensive income for the period, net of tax |      | 8,392               | 52,139              |
| Total comprehensive income/(loss) for the period      |      | 69,021              | (192,728)           |
| Total comprehensive income/(loss) attributable to:    |      |                     |                     |
| - Owners of the Company                               |      | 65,040              | (192,479)           |
| - Non-controlling interests                           |      | 3,981               | (249)               |
|   |      | 69,021              | (192,728)           |

The accompanying notes form an integral part of the interim condensed consolidated financial information.

## **Interim Condensed Consolidated Statement of Financial Position**

As at 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

|   | Note  | As at<br>30 June 2024<br>(unaudited) | As at 31 December 2023 |
|---|-------|--------------------------------------|------------------------|
| ASSETS  |       |                                      |                        |
| Non-current assets                                    |       |                                      |                        |
| Goodwill  | 13    | 1,677,692                            | 1,677,692              |
| Right-of-use assets                                   | 14    | 43,841                               | 80,951                 |
| Property, plant and equipment                         | 15    | 73,405                               | 85,682                 |
| Other intangible assets                               | 16    | 32,170                               | 42,489                 |
| Investments in associates and joint ventures          | 17    | 108,944                              | 109,212                |
| Term deposits   | 22(c) | 1,412,320                            | 1,196,614              |
| Total non-current assets                              |       | 3,348,372                            | 3,192,640              |
| Current assets  |       |                                      |                        |
| Inventories   | 18    | 125,934                              | 198,575                |
| Trade receivables                                     | 19    | 956,683                              | 1,190,392              |
| Contract related assets                               | 6     | 190,411                              | 159,215                |
| Prepayments and other receivables                     | 20    | 341,389                              | 347,919                |
| Financial assets at fair value through profit or loss | 21    | 5,938,934                            | 5,330,666              |
| Restricted cash                                       | 22(b) | 75,074                               | 84,796                 |
| Term deposits   | 22(c) | 2,209,771                            | 4,149,327              |
| Cash and cash equivalents                             | 22(a) | 3,008,655                            | 1,866,511              |
| Total current assets                                  |       | 12,846,851                           | 13,327,401             |
| Total assets  |       | 16,195,223                           | 16,520,041             |

## **Interim Condensed Consolidated Statement of Financial Position**

As at 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

|  | Note | As at<br>30 June 2024<br>(unaudited) | As at<br>31 December 2023 |
|--|------|--------------------------------------|---------------------------|
| EQUITY AND LIABILITIES                             |      |                                      |                           |
| Equity   |      |                                      |                           |
| Share capital                                      | 23   | 35                                   | 35                        |
| Treasury shares                                    |      | (1)                                  | (1)                       |
| Reserves   | 24   | 20,536,152                           | 20,497,766                |
| Accumulated losses                                 |      | (7,157,522)                          | (7,214,170)               |
| Total equity attributable to owners of the Company |      | 13,378,664                           | 13,283,630                |
| Non-controlling interests                          |      | (12,663)                             | (16,644)                  |
| Total equity                                       |      | 13,366,001                           | 13,266,986                |
| Liabilities  |      |                                      |                           |
| Non-current liabilities                            |      |                                      |                           |
| Lease liabilities                                  | 14   | 19,734                               | 49,989                    |
| Trade and other payables                           | 26   | 11,242                               | 10,990                    |
| Provisions   | 27   | 95,000                               | 95,000                    |
| Total non-current liabilities                      |      | 125,976                              | 155,979                   |
| Current liabilities                                |      |                                      |                           |
| Trade and other payables                           | 26   | 1,707,102                            | 2,201,371                 |
| Contract liabilities                               | 6    | 967,128                              | 852,084                   |
| Lease liabilities                                  | 14   | 29,016                               | 43,621                    |
| Total current liabilities                          |      | 2,703,246                            | 3,097,076                 |
| Total liabilities                                  |      | 2,829,222                            | 3,253,055                 |
| Total equity and liabilities                       |      | 16,195,223                           | 16,520,041                |

The interim condensed consolidated financial information and the accompanying notes starting from page 33 to page 72 are signed by:

> **WU Jun** LI Dou (Director) (Director)

The accompanying notes form an integral part of the interim condensed consolidated financial information.

# **Interim Condensed Consolidated Statement of Changes in Equity**

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

|  |      | For the six months ended 30 June 2024 (unaudited) Attributable to owners of the Company |            |                    |                    |            |                                  |                 |  |
|--|------|---|------------|--------------------|--------------------|------------|----------------------------------|-----------------|--|
|  | Note | Share capital   | Reserves   | Treasury<br>shares | Accumulated losses | Total      | Non-<br>controlling<br>interests | Total<br>equity |  |
| As at 1 January 2024                             |      | 35  | 20,497,766 | (1)                | (7,214,170)        | 13,283,630 | (16,644)                         | 13,266,986      |  |
| Profit for the period Other comprehensive income |      | -   | -          | -                  | 56,648             | 56,648     | 3,981                            | 60,629          |  |
| for the period                                   |      | -   | 8,392      | -                  | -                  | 8,392      | -                                | 8,392           |  |
| Share-based payments                             | 25   | -   | 29,833     | -                  | -                  | 29,833     | -                                | 29,833          |  |
| Exercise of share options                        | 25   | -   | 161        | -                  | -                  | 161        | -                                | 161             |  |
| As at 30 June 2024                               |      | 35  | 20,536,152 | (1)                | (7,157,522)        | 13,378,664 | (12,663)                         | 13,366,001      |  |

|   |      | For the six months ended 30 June 2023 (unaudited) Attributable to owners of the Company |            |                    |                    |            |                                  |                 |  |
|---|------|---|------------|--------------------|--------------------|------------|----------------------------------|-----------------|--|
|   | Note | Share<br>capital  | Reserves   | Treasury<br>shares | Accumulated losses | Total      | Non-<br>controlling<br>interests | Total<br>equity |  |
| As at 1 January 2023 as originally presented    |      | 35  | 20,423,914 | (1)                | (6,964,368)        | 13,459,580 | (1,072)                          | 13,458,508      |  |
| Change in accounting policy                     |      | -   | -          | -                  | 72,792             | 72,792     | -                                | 72,792          |  |
| As at 1 January 2023 restated                   |      | 35  | 20,423,914 | (1)                | (6,891,576)        | 13,532,372 | (1,072)                          | 13,531,300      |  |
| Loss for the period                             |      | -   | -          | -                  | (244,618)          | (244,618)  | (249)                            | (244,867)       |  |
| Other comprehensive income for the period       |      | -   | 52,139     | -                  | -                  | 52,139     | -                                | 52,139          |  |
| Share-based payments                            | 25   | -   | 5,912      | -                  | -                  | 5,912      | -                                | 5,912           |  |
| Exercise of share options                       | 25   | -   | 4,606      | -                  | -                  | 4,606      | -                                | 4,606           |  |
| Disposal of equity interests in a joint venture |      | -   | (1,823)    | -                  | -                  | (1,823)    | -                                | (1,823)         |  |
| Share of other reserves of associates           |      | -   | 2,434      | -                  | -                  | 2,434      | -                                | 2,434           |  |
| As at 30 June 2023                              |      | 35  | 20,487,182 | (1)                | (7,136,194)        | 13,351,022 | (1,321)                          | 13,349,701      |  |

The accompanying notes form an integral part of the interim condensed consolidated financial information.

# **Interim Condensed Consolidated Statement of Cash Flows**

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

|   |      | Six months ende        | ed 30 June                              |
|---|------|------------------------|---|
|   | Note | 2024                   | 2023                                    |
|   |      | (unaudited)            | (unaudited)                             |
| Cash flows from operating activities  |      |                        |   |
| Cash used in operations   |      | (134,694)              | (65,504)                                |
| Income tax paid   |      | (313)                  | (1,758)                                 |
| Net cash used in operating activities                                       |      | (135,007)              | (67,262)                                |
| Cash flows from investing activities  |      |                        |   |
| Proceeds from disposal of property, plant and                               |      |                        |   |
| equipment and intangible assets   |      | 618                    | 248                                     |
| Payments for property, plant and equipment and                              |      |                        | /·= · ·                                 |
| intangible assets   |      | (10,536)               | (17,138)                                |
| Payments for acquisition of subsidiaries, net of cash                       |      |                        | (69,944)                                |
| acquired  Payments for financial assets at fair value through profit        |      | _                      | (09,944)                                |
| or loss   |      | (6,517,000)            | (2,754,705)                             |
| Proceeds from sales of financial assets at fair value                       |      | <b>(</b> 2, <b>)</b> 2 | ( , , , , , , , , , , , , , , , , , , , |
| through profit or loss  |      | 6,008,615              | 4,627,499                               |
| Proceeds from sales of financial assets at amortized                        |      |                        |   |
| cost  |      | -                      | 511,987                                 |
| Payments for term deposits with initial term of over                        |      |                        |   |
| three months  |      | (1,313,123)            | (1,665,901)                             |
| Interest received from term deposits with initial term of over three months |      | 027 717                | 42.110                                  |
| Proceeds from term deposits with initial term of over                       |      | 237,717                | 42,119                                  |
| three months  |      | 2,888,781              | 300,000                                 |
| Proceeds from disposal of investments in a joint venture                    |      | -                      | 10,388                                  |
| Net cash generated from investing activities                                |      | 1,295,072              | 984,553                                 |
| Cash flows from financing activities  |      |                        |   |
| Payments for lease liabilities  |      | (18,901)               | (39,839)                                |
| Proceeds from exercise of share options                                     |      | 161                    | 4,606                                   |
| Proceeds from borrowings  |      | -                      | 10,500                                  |
| Repayments for borrowings   |      | -                      | (4,000)                                 |
| Net cash used in financing activities                                       |      | (18,740)               | (28,733)                                |
| Net increase in cash and cash equivalents                                   |      | 1,141,325              | 888,558                                 |
| Cash and cash equivalents at the beginning of the period                    | 22   | 1,866,511              | 3,700,689                               |
| Effects of exchange rate changes on cash and cash                           |      |                        |   |
| equivalents   |      | 819                    | 6,011                                   |
| Cash and cash equivalents at the end of the period                          | 22   | 3,008,655              | 4,595,258                               |

The accompanying notes form an integral part of the interim condensed consolidated financial information.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### **GENERAL INFORMATION**

Ping An Healthcare and Technology Company Limited (formerly known as "Glorious Health Limited") (the "Company") was incorporated in the Cayman Islands on 12 November 2014 as an exempted company with limited liability under the Companies Law (Cap. 22, Law 3 of 1961 as consolidated and revised) of the Cayman Islands. The address of the Company's registered office is PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.

The Company's shares have been listed on the Main Board of the Stock Exchange of Hong Kong Limited since 4 May 2018 by way of its initial public offering.

The Company is an investment holding company. The Company and its subsidiaries (together, the "Group") are principally engaged in offering medical and health services through the Group's mobile platform in the People's Republic of China (the "PRC").

Glorious Peace Limited ("Glorious Peace") is the major shareholder of the Company, holding 39.41% of the shareholding interest in the Company as at 30 June 2024.

#### 2 BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICIES

#### 2.1 Basis of preparation

This interim condensed consolidated financial information for the six months ended 30 June 2024 has been prepared in accordance with International Accounting Standard 34 "Interim Financial Reporting" issued by the International Accounting Standards Board ("IASB"), as part of the International Financial Reporting Standards ("IFRS Accounting Standards").

This interim condensed consolidated financial information does not include all the information and disclosures normally included in the annual financial statements, and should be read in conjunction with the Group's annual financial statements for the year ended 31 December 2023 and any public announcements made by the Group during the interim reporting period.

#### 2.2 Material accounting policies

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2023, except for the adoption of new or amended standards and interpretations since 1 January 2024.

#### (a) New and amended standards adopted by the Group

The Group has applied the following standards and amendments for the first time to financial reporting periods commencing 1 January 2024.

Amendments to IAS 1 Classification of Liabilities as Current or Non-current

Non-current liabilities with covenants

Amendments to IFRS 16 Lease liability in sale and leaseback Amendments to IAS 7 and IFRS 7 Supplier Finance Arrangements

The amendments listed above did not have any impact on the amounts recognized in prior periods and are not expected to significantly affect the current or future periods.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 2 BASIS OF PREPARATION AND MATERIAL ACCOUNTING POLICIES (Continued)

#### 2.2 Material accounting policies (Continued)

(b) New and amended standards issued but not yet adopted by the Group

Standards, amendments and interpretations that have been issued but not yet effective for the financial year beginning 1 January 2024 and not been early adopted by the Group as at the reporting period are as follows:

|                                 |   | Effective for annual periods beginning on or after |
|---------------------------------|---|--|
| Amendments to IAS 21            | Lack of Exchangeability                                 | 1 January 2025                                     |
| Amendments to IFRS 7 and IFRS 9 | Classification and measurement of financial instruments | 1 January 2026                                     |
| IFRS 18                         | Presentation and Disclosure in Financial Statements     | 1 January 2027                                     |
| IFRS 19                         | Subsidiaries without Public Accountability: Disclosures | 1 January 2027                                     |

The Group has already commenced an assessment of the impact of the new or revised standards that have been issued but either not yet effective for the financial period beginning 1 January 2024 or not been early adopted by the Group which are relevant to the Group's operation. The adoption of IFRS 18 is expected to impact presentation and disclosure in financial information.

Apart form IFRS 18, the Group believes that the application of other amendments to IFRSs, amendments to IASs and the new interpretations is unlikely to have a material impact on the Group's statement of financial position and performance as well as disclosure in the future.

#### **ESTIMATES**

The preparation of interim condensed consolidated financial information requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing this interim condensed consolidated financial information, the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the Group's annual financial statements for the year ended 31 December 2023.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### **4 MANAGEMENT OF FINANCIAL RISK**

#### 4.1 Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including foreign currency risk, price risk and interest rate risk), credit risk and liquidity risk.

The interim condensed consolidated financial information does not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements as at 31 December 2023.

There have been no changes in the risk management policies for the Group since year end.

#### 4.2 Liquidity risk

The Group aims to maintain sufficient cash and cash equivalents and marketable securities to mitigate its liquidity risk. Due to the dynamic nature of the underlying businesses, the Group maintains flexibility in funding by maintaining adequate cash and cash equivalents.

The table below analyzes the Group's financial liabilities into relevant maturity grouping based on the remaining period at the end of each reporting period to the contractual maturity date. The amounts disclosed in the table are undiscounted contractual cash flows.

|                          |              | As at 30 June 2024 |                 |                 |         |           |  |  |
|--------------------------|--------------|--------------------|-----------------|-----------------|---------|-----------|--|--|
|                          | On<br>demand | Within 1<br>year   | 1 to 5<br>years | Over 5<br>years | Undated | Total     |  |  |
| Liabilities:             |              |                    |                 |                 |         |           |  |  |
| Lease liabilities        | -            | 29,141             | 20,412          | -               | -       | 49,553    |  |  |
| Trade and other payables | -            | 1,156,170          | 11,996          | -               | 48      | 1,168,214 |  |  |
|                          | -            | 1,185,311          | 32,408          | -               | 48      | 1,217,767 |  |  |

|                          | As at 31 December 2023 |                  |                 |                        |         |           |  |
|--------------------------|------------------------|------------------|-----------------|------------------------|---------|-----------|--|
|                          | On<br>demand           | Within 1<br>year | 1 to 5<br>years | Over <b>5</b><br>vears | Undated | Total     |  |
| Liabilities:             |                        |                  | <b>J</b> 14 1   |                        |         |           |  |
| Lease liabilities        | -                      | 44,952           | 52,381          | _                      | _       | 97,333    |  |
| Trade and other payables | -                      | 1,525,259        | 11,996          | -                      | 48      | 1,537,303 |  |
|                          | -                      | 1,570,211        | 64,377          | -                      | 48      | 1,634,636 |  |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 4 MANAGEMENT OF FINANCIAL RISK (Continued)

#### 4.3 Fair value estimation

Fair value estimates are made at a specific point in time based on relevant market information and information about financial instruments. When an active market exists, such as an authorized securities exchange, the market value is the best reflection of the fair values of financial instruments. For financial instruments that there is no active market, fair value is determined using valuation techniques.

The Group's financial assets mainly include financial assets at fair value through profit or loss.

#### Determination of fair value and fair value hierarchy

All assets and liabilities for which fair value is measured or disclosed in the consolidated financial statements are categorised within the fair value hierarchies. The fair value hierarchy categorizes the inputs to valuation techniques used to measure fair value into three broad levels. The level in the fair value hierarchy within which the fair value measurement is categorized in its entirety is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety.

The levels of the fair value hierarchy are as follows:

- (a) Fair value is based on quoted prices (unadjusted) in active markets for identical assets or liabilities ("Level 1");
- (b) Fair value is based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices) ("Level 2"); and
- (c) Fair value is based on inputs for the asset or liability that are not based on observable market data (unobservable inputs) ("Level 3").

The level of fair value calculation is determined by the lowest level input that is significant in the overall calculation. As such, the significance of the input should be considered from an overall perspective in the calculation of fair value.

For Level 2 financial instruments, valuations are generally obtained from third party pricing services for identical or comparable assets, or through the use of valuation methodologies using observable market inputs, or recent quoted market prices. Valuation service providers typically gather, analyze and interpret information related to market transactions and other key valuation model inputs from multiple sources, and through the use of widely accepted internal valuation models, provide a theoretical quote on various securities.

For Level 3 financial instruments, prices are determined using valuation methodologies such as discounted cash flow models and other similar techniques. Determinations to classify fair value measurement within Level 3 of the valuation hierarchy are generally based on the significance of the unobservable factors to the overall fair value measurement, and valuation methodologies such as discounted cash flow models and other similar techniques.

For assets and liabilities that are recognized at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the six months ended 30 June 2024

969,537

5,330,666

(All amounts expressed in RMB thousand unless otherwise stated)

4,361,129

### 4 MANAGEMENT OF FINANCIAL RISK (Continued)

#### 4.3 Fair value estimation (Continued)

Determination of fair value and fair value hierarchy (Continued)

The following tables provide the fair value measurement hierarchy of the Group's financial assets and liabilities:

|                                |         | As at 30 Ju   | ne 2024   |           |
|--------------------------------|---------|---------------|-----------|-----------|
|                                | Level 1 | Level 2       | Level 3   | Total     |
| Assets measured at fair value  |         |               |           |           |
| Financial assets at fair value |         |               |           |           |
| through profit or loss         | -       | 4,303,831     | 1,635,103 | 5,938,934 |
|                                |         |               |           |           |
|                                |         | As at 31 Dece | mber 2023 |           |
|                                | Level 1 | Level 2       | Level 3   | Total     |
| Assets measured at fair value  |         |               |           |           |

For the period, there were no transfers among different levels of fair values measurement.

#### Valuation techniques

Financial assets at fair value through profit or loss

The fair value of the unquoted equity investments has been determined using valuation techniques such as comparable company valuation multiples, recent transaction prices of the same or similar instruments, with appropriate adjustments made where applicable, for example, for lack of liquidity using option pricing models. The valuation requires management to make certain assumptions about unobservable inputs to the model, which mainly include historical volatility and estimated time period prior to the listing of the unquoted equity instruments, etc. The fair value of the unquoted equity investments is immaterial to the Group.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 5 SCOPE OF CONSOLIDATION

Particulars of the subsidiaries and entities in the scope of consolidation of the Group at 30 June 2024 are set out below:

#### (a) Subsidiaries

| Company name  | Place and date of incorporation/ establishment     | Issued and paid-in capital |                 | e economic<br>the Group | Principal activities/ Place of operations | Notes |
|---|--|----------------------------|-----------------|-------------------------|---|-------|
|   |  |                            | 30 June<br>2024 | 31 December<br>2023     |   |       |
| Directly owned:   |  |                            |                 |                         |   |       |
| Glorious Delight Limited  | Hong Kong/<br>14 November 2014                     | USD931,574,773             | 100%            | 100%                    | Investment Holding/<br>Hong Kong          |       |
| Le An Xin (PTC) Limited ("Le An Xin")<br>(Note 25)                    | British Virgin Islands ("BVI")/<br>17 October 2017 | USD0                       | -               | -                       | Investment Holding/<br>BVI                |       |
| Good Doctor Online Healthcare Limited                                 | Cayman Islands/<br>23 July 2018                    | USD21,950,001              | 100%            | 100%                    | Investment Holding/<br>Cayman Islands     |       |
| Yu Kang Limited   | Hong Kong/<br>12 December 2018                     | HKD1<br>USD21,000,000      | 100%            | 100%                    | Investment Holding/<br>Hong Kong          |       |
| Indirectly owned:   |  |                            |                 |                         |   |       |
| Scientia Smart Health Technologies Limited                            | Cayman Islands/<br>18 May 2022                     | USD280                     | 100%            | 100%                    | Investment Holding/<br>Cayman Islands     |       |
| Scientia Smart Health Technologies (BVI)<br>Limited                   | BVI/<br>25 May 2022                                | USD0                       | 100%            | 100%                    | Investment Holding/<br>BVI                |       |
| Scientia Smart Health Technologies (HK)<br>Limited                    | Hong Kong/<br>30 May 2022                          | HKD0                       | 100%            | 100%                    | Investment Holding/<br>Hong Kong          |       |
| Shenzhen Ping An Intelligent Medical<br>Technology Co., Ltd.          | the PRC/<br>27 July 2022                           | RMB0                       | 100%            | 100%                    | Technology Service/<br>the PRC            |       |
| Kang Jian Information Technology<br>(Shenzhen) Co., Ltd ("Kang Jian") | the PRC/<br>13 February 2015                       | USD1,430,921,643           | 100%            | 100%                    | Investment Holding/<br>the PRC            |       |
| Jiangsu Zhongyikang Pharmaceutical<br>Company Limited                 | the PRC/<br>14 December 2006                       | RMB5,000,000               | 100%            | 100%                    | Medicine Marketing/<br>the PRC            |       |
| Shanghai Yiteng Enterprise Management<br>Consulting Co., Ltd          | the PRC/<br>21 November 2016                       | RMB3,000,000               | 100%            | 100%                    | Technology Service/<br>the PRC            |       |
| Shanghai Kangrong Pharmacy Co., Ltd.                                  | the PRC/<br>21 May 2019                            | RMB10,000,000              | 100%            | 100%                    | Medicine Marketing/<br>the PRC            |       |
| Hefei Yunshantang Nuoke Pharmacy Co., Ltd.                            | the PRC/<br>4 November 2021                        | RMB1,260,000               | 100%            | 100%                    | Medicine Marketing/<br>the PRC            |       |
| Hefei Yunshantang Nuorui Pharmacy Co., Ltd.                           | the PRC/<br>4 November 2021                        | RMB1,210,000               | 100%            | 100%                    | Medicine Marketing/<br>the PRC            |       |
| Hefei Yunshantang Pharmacy Co., Ltd.                                  | the PRC/<br>25 April 2022                          | RMB1,210,000               | 100%            | 100%                    | Medicine Marketing/<br>the PRC            |       |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

## 5 SCOPE OF CONSOLIDATION (Continued)

#### (a) Subsidiaries (Continued)

| Company name   | Place and date of incorporation/ Issued and establishment paid-in capital |                | Attributable economic interest to the Group |                     | Principal activities/ Place of operations Notes  |  |
|--|---|----------------|---|---------------------|--|--|
|  |   |                | 30 June<br>2024                             | 31 December<br>2023 |  |  |
| Controlled by the Company pursuant to the Co                                 | ontractual Agreements:  |                |   |                     |  |  |
| Ping An Health Cloud Company Limited ("PAHC")                                | the PRC/<br>20 August 2014  | RMB350,000,000 | 100%  | 100%                | Development<br>and operation of apps/<br>the PRC |  |
| Jiangxi Pingan Health Pharmacy Company<br>Limited                            | the PRC/<br>24 January 2014   | RMB2,000,000   | 100%  | 100%                | Medicine Marketing/<br>the PRC                   |  |
| Tianjin Kuaiyijie Medical Electronic Commerce<br>Company Limited             | the PRC/<br>29 March 2005   | RMB15,000,000  | 100%  | 100%                | Technology<br>Development/<br>the PRC            |  |
| Qingdao Ping An Kangjian Internet Hospital<br>Co., Ltd.                      | the PRC/<br>24 April 2017   | RMB10,000,000  | 100%  | 100%                | Internet Hospital/<br>the PRC                    |  |
| Hefei Ping An Kangjian Internet Hospital<br>Company Limited                  | the PRC/<br>21 September 2017   | RMB7,810,000   | 100%  | 100%                | Internet Hospital/<br>the PRC                    |  |
| Jiangsu Nabaite Pharmacy Company Limited                                     | the PRC/<br>11 October 2017   | RMB10,000,000  | 100%  | 100%                | Medicine Marketing/<br>the PRC                   |  |
| Yinchuan Pingan Kangjian Internet Hospital<br>Company Limited                | the PRC/<br>12 March 2018   | RMB5,500,000   | 100%  | 100%                | Internet Hospital/<br>the PRC                    |  |
| Pingan Wanjia Healthcare Management<br>Company Limited ("Wanjia Healthcare") | the PRC/<br>4 July 2016   | RMB400,000,000 | 100%  | 100%                | Technology<br>Development/<br>the PRC            |  |
| Shanghai Pingan Wanjia Healthcare<br>Management Company Limited              | the PRC/<br>8 December 2016   | RMB100,000,000 | 100%  | 100%                | Technology<br>Development/<br>the PRC            |  |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

## 5 SCOPE OF CONSOLIDATION (Continued)

### (a) Subsidiaries (Continued)

|  | ~ /  |                            |      |  |  |       |
|--|--|----------------------------|------|--|--|-------|
| Company name   | Place and date of incorporation/ establishment | Issued and paid-in capital |      | e economic<br>the Group<br>31 December<br>2023 | Principal activities/<br>Place of operations | Notes |
| Controlled by the Company pursuant to the C                                  | ontractual Agreements (Con                     | tinued):                   |      |  |  |       |
| Shenzhen Pingan Wanjia Healthcare<br>Investment Company Limited              | the PRC/<br>11 August 2016                     | RMB<br>30,000,000          | 100% | 100%   | Investment Holding/ the PRC                  |       |
| Xiamen Wanjia Healthcare Investment<br>Company Limited                       | the PRC/<br>6 December 2016                    | RMB<br>20,000,000          | 100% | 100%   | Investment Holding/<br>the PRC               |       |
| Xiamen Siming Wanjia TCM Outpatient<br>Department Co., Ltd.                  | the PRC/<br>26 July 2017                       | RMB<br>11,000,000          | 100% | 100%   | Clinic/<br>the PRC                           |       |
| Shenzhen Anan Outpatient Service<br>Department                               | the PRC/<br>20 June 2017                       | RMB<br>400,000             | 100% | 100%   | Clinic/<br>the PRC                           |       |
| Pingan Health Insurance Agency Co. Ltd                                       | the PRC/<br>10 February 2011                   | RMB<br>50,000,000          | 70%  | 70%  | Insurance Agency/<br>the PRC                 |       |
| Guangzhou Jifan Biotechnology Company<br>Limited                             | the PRC/<br>23 July 2015                       | RMB<br>10,000,000          | 100% | 100%   | Medicine Marketing/<br>the PRC               |       |
| Hainan Ping An Health and Technology<br>Company Limited                      | the PRC/<br>15 October 2019                    | RMB<br>5,110,000           | 100% | 100%   | Technology<br>Development/<br>the PRC        |       |
| Hebei Nabaite Pharmacy Company Limited                                       | the PRC/<br>28 December 2019                   | RMB<br>10,000,000          | 100% | 100%   | Medicine Marketing/<br>the PRC               |       |
| Pingan Yingjian Medical Management<br>(Shanghai) Limited ("Pingan Yingjian") | the PRC/<br>24 April 2015                      | RMB<br>35,000,000          | 50%  | 50%  | Medical Service/<br>the PRC                  |       |
| Shanghai Yingjian Clinics Co., Ltd   | the PRC/<br>12 December 2016                   | RMB<br>10,000,000          | 50%  | 50%  | Clinic/<br>the PRC                           |       |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

## 5 SCOPE OF CONSOLIDATION (Continued)

#### (a) Subsidiaries (Continued)

| Company name   | Place and date of incorporation/ establishment | Issued and paid-in capital |                 | e economic<br>the Group | Principal activities/<br>Place of operations | Notes |
|--|--|----------------------------|-----------------|-------------------------|--|-------|
|  |  |                            | 30 June<br>2024 | 31 December<br>2023     |  |       |
| Controlled by the Company pursuant to the Co                             | ontractual Agreements (Cont                    | inued):                    |                 |                         |  |       |
| Guangxi Pingan Good Doctor Internet<br>Hospital Company Limited          | the PRC/<br>13 April 2020                      | RMB<br>3,670,000           | 51%             | 51%                     | Internet Hospital/<br>the PRC                |       |
| Chengdu Ping An Kangjian Internet Hospital<br>Management Company Limited | the PRC/<br>14 January 2020                    | RMB<br>50,000,000          | 100%            | 100%                    | Internet Hospital/<br>the PRC                |       |
| Shanghai No. 8 Ping An Good Doctor Internet<br>Hospital Co., Ltd.        | the PRC/<br>11 June 2020                       | RMB<br>20,000,000          | 100%            | 100%                    | Internet Hospital/<br>the PRC                |       |
| Tianjin Pingan Kangjian Internet Hospital<br>Co., Ltd.                   | the PRC/<br>27 September 2020                  | RMB<br>831,000             | 100%            | 100%                    | Internet Hospital/<br>the PRC                |       |
| Guangzhou Kangjian Internet Hospital Co.,<br>Ltd.                        | the PRC/<br>2 December 2020                    | RMB<br>0                   | 100%            | 100%                    | Internet Hospital/<br>the PRC                |       |
| Ping An Health (Jiangsu) Internet Co., Ltd.                              | the PRC/<br>17 November 2020                   | RMB<br>30,000,000          | 100%            | 100%                    | Internet Hospital/<br>the PRC                |       |
| Ping An Yingxiang (Jiaxing) Software Co.,<br>Ltd.                        | the PRC/<br>22 March 2011                      | RMB<br>650,480             | 100%            | 100%                    | Technology Development/ the PRC              |       |
| Shanghai Mengchong Information Technology<br>Co., Ltd.                   | the PRC/<br>21 October 2021                    | RMB<br>80,000,000          | 100%            | 100%                    | Technology<br>Development/<br>the PRC        |       |

All of the subsidiaries of the Company established in the PRC were limited liability company, with registered Chinese name.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### REVENUE AND SEGMENT INFORMATION

The Group's business activities, for which discrete financial statements are available, are regularly reviewed and evaluated by Chief Operation Decision Maker ("CODM"). CODM, who is responsible for allocating resources and assessing performance of the operating segment, has been identified as the executive directors of the Company that make strategic decisions. As a result of this evaluation, the Group determined that it has operating segments as follows:

- Medical services
- Health services
- Senior care services

CODM has changed the structure of internal organization in a manner that causes the composition of the Group's reportable segments to change. During the reporting period, the Group separated Senior care services segment as an independent segment to better reflect the Group's operating strategy. The corresponding items of segment information for earlier period has been restated.

CODM assesses the performance of the operating segments mainly based on segment revenue and gross profit of each operating segment which is used by management as a basis for the purpose of resource allocation and assessment of segment performance. The selling and marketing expenses and administrative expenses are not included in the measurement of the segments' performance. Other income, other gains net, finance income - net, share of losses of associates and joint ventures, and income tax expense are also not allocated to individual operating segments.

Revenues from external customers reported to CODM are measured as segment revenue, which is derived from the customers in each segment. Cost of revenue primarily comprises cost of medical service fee, inventories consumed, salary and compensation expenses, and others.

The segment information provided to CODM is measured in a manner consistent with that applied in these financial statements. There was no information on separate segment assets or segment liabilities provided to CODM, as CODM does not use such information to allocate resources to or evaluate the performance of the operating segments.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

## **6 REVENUE AND SEGMENT INFORMATION (Continued)**

The segment information reported to CODM for the reporting period is as follows:

| For the period ended of 30 June 2024 | Medical<br>services | Health<br>services | Senior care services | Total       |
|--------------------------------------|---------------------|--------------------|----------------------|-------------|
| Revenue from customers               | 1,062,743           | 983,392            | 47,314               | 2,093,449   |
| Cost of sales                        | (640,507)           | (739,819)          | (39,325)             | (1,419,651) |
| Gross Profit                         | 422,236             | 243,573            | 7,989                | 673,798     |

| For the period ended of 30 June 2023 | Medical<br>services | Health<br>services | Senior care<br>services | Total       |
|--------------------------------------|---------------------|--------------------|-------------------------|-------------|
| Revenue from customers               | 1,031,559           | 1,175,093          | 15,525                  | 2,222,177   |
| Cost of sales                        | (587,671)           | (904,136)          | (15,008)                | (1,506,815) |
| Gross Profit                         | 443,888             | 270,957            | 517                     | 715,362     |

The Company is domiciled in the Cayman Islands while the Group mainly operates its businesses in the PRC and earns substantially all of the revenues from external customers in the PRC.

As at 30 June 2024 and 31 December 2023, most of the non-current assets of the Group were located in the PRC.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

## **6 REVENUE AND SEGMENT INFORMATION (Continued)**

#### (a) Disaggregation of revenue from contracts with customers

| For the period ended of 30 June 2024 | Medical<br>services | Health<br>services | Senior care services | Total     |
|--------------------------------------|---------------------|--------------------|----------------------|-----------|
| By nature                            |                     |                    |                      |           |
| Services and Sales of goods          | 986,779             | 954,393            | 47,314               | 1,988,486 |
| Commission income                    | 75,964              | 28,999             |                      | 104,963   |
|                                      | 1,062,743           | 983,392            | 47,314               | 2,093,449 |
| Timing of revenue recognition        |                     |                    |                      |           |
| At a point in time                   | 888,474             | 971,267            | 46,866               | 1,906,607 |
| Overtime                             | 174,269             | 12,125             | 448                  | 186,842   |
|                                      | 1,062,743           | 983,392            | 47,314               | 2,093,449 |
|                                      |                     |                    |                      |           |
| For the period ended of              | Medical             | Health             | Senior care          |           |
| 30 June 2023                         | services            | services           | services             | Total     |
| By nature                            |                     |                    |                      |           |
| Services and Sales of goods          | 955,186             | 1,151,744          | 15,525               | 2,122,455 |
| Commission income                    | 76,373              | 23,349             | -                    | 99,722    |
|                                      | 1,031,559           | 1,175,093          | 15,525               | 2,222,177 |
| Timing of revenue recognition        |                     |                    |                      |           |
| At a point in time                   | 719,934             | 1,153,347          | 15,525               | 1,888,806 |
| Overtime                             | 311,625             | 21,746             | -                    | 333,371   |

#### (b) Contract related assets and liabilities

The Group has recognized the following revenue-related contract related assets and liabilities.

|                      | As at 30 June As at 31 December |         |
|----------------------|---------------------------------|---------|
|                      | 2024                            | 2023    |
| Contract assets      |                                 |         |
| Medical services     | 117,581                         | 110,195 |
| Health services      | 72,830                          | 49,020  |
|                      | 190,411                         | 159,215 |
| Contract liabilities |                                 |         |
| Medical services     | 423,121                         | 406,043 |
| Health services      | 543,944                         | 446,041 |
| Senior care services | 63                              | -       |
|                      | 967,128                         | 852,084 |

1,031,559

1,175,093

2,222,177

15,525

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### **7 EXPENSES BY NATURE**

|   |           | For the six months ended 30 June |  |
|---|-----------|----------------------------------|--|
|   | 2024      | 2023                             |  |
| Cost of merchandise                                   | 708,737   | 744,261                          |  |
| Cost for service fee paid to venders                  | 652,444   | 659,694                          |  |
| Employee benefit expenses                             | 343,921   | 707,402                          |  |
| Direct sale and business development fee (Note a)     | 245,138   | 291,678                          |  |
| Consulting expenses                                   | 67,021    | 84,847                           |  |
| Depreciation of right-of-use assets                   | 21,887    | 35,203                           |  |
| Travelling, entertainment and general office expenses | 20,626    | 30,045                           |  |
| Depreciation of property, plant and equipment         | 20,323    | 31,634                           |  |
| Labour outsourcing expenses                           | 20,190    | 22,534                           |  |
| Postage and communication expenses                    | 20,113    | 25,891                           |  |
| Settlement expenses                                   | 11,674    | 7,667                            |  |
| Amortization of other intangible assets               | 10,319    | 18,289                           |  |
| Leasing expenses                                      | 4,190     | 5,551                            |  |
| Tax and surcharges                                    | 3,101     | 6,463                            |  |
| Remuneration of the auditors                          | 2,200     | 2,250                            |  |
| Others  | 29,102    | 40,423                           |  |
|   | 2,180,986 | 2,713,832                        |  |

Note:

#### **OTHER INCOME**

|   | For the six months ended 30 June |        |  |
|---|----------------------------------|--------|--|
|   | 2024                             |        |  |
| Investment income on short-term investments placed with |                                  |        |  |
| banks   | 16,674                           | 13,214 |  |
| Government grants                                       | 1,610                            | 29,983 |  |
| Interest on financial assets at amortized cost          | -                                | 12,077 |  |
|   | 18,284                           | 55,274 |  |

<sup>(</sup>a) The direct sale and business development fee includes commission expenses, advertising expenses and promotion expenses.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 9 OTHER GAINS - NET

|  | For the six months ended 30 June |         |
|--|----------------------------------|---------|
|  | 2024                             | 2023    |
| Net fair value gains on financial assets at fair value through |                                  |         |
| profit or loss   | 80,469                           | 56,148  |
| Net foreign exchange gains/(losses)                            | 723                              | (1,899) |
| Net gains on disposals of a joint venture                      | -                                | 12,211  |
| Impairment (provision)/reversal for financial assets           | (63,576)                         | 5,272   |
| Others   | 10,121                           | 7,559   |
|  | 27,737                           | 79,291  |

#### **10 FINANCE INCOME - NET**

|  | For the six months ended 30 June |         |
|--|----------------------------------|---------|
|  | 2024                             | 2023    |
| Finance income                         |                                  |         |
| Interest income                        | 103,977                          | 119,285 |
| Finance costs                          |                                  |         |
| Interest expenses on lease liabilities | (1,289)                          | (3,798) |
| Interest expenses on borrowings        | (252)                            | (245)   |
|  | 102,436                          | 115,242 |

#### 11 INCOME TAX EXPENSE

The income tax expense of the Group for the period ended 30 June 2024 is analyzed as follows:

|                    | For the six months ended 30 June |      |
|--------------------|----------------------------------|------|
|                    | 2024                             | 2023 |
| Current income tax | 23                               | 604  |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

### 11 INCOME TAX EXPENSE (Continued)

The tax on the Group's profit/(loss) before income tax differs from the theoretical amount that would arise using the statutory tax rate applicable to loss of the consolidated entities as follows:

|  | For the six months ended 30 June |           |
|--|----------------------------------|-----------|
|  | 2024                             | 2023      |
| Profit/(Loss) before income tax                            | 60,652                           | (244,263) |
| Tax calculated at PRC statutory income tax rate of 25%     | 15,163                           | (61,066)  |
| Tax effects of   |                                  |           |
| - Differential income tax rates applicable to subsidiaries |                                  |           |
| (Note a) (Note b)  | (18,959)                         | (10,924)  |
| - Tax losses and temporary differences for which no        |                                  |           |
| deferred income tax asset was recognized                   | 48,059                           | 23,433    |
| - Expense not deductible for tax purposes                  | 61,144                           | 52,253    |
| - PRC withholding income tax                               | 21                               | 999       |
| - Previously unrecognized tax losses now recouped to       |                                  |           |
| reduce current tax expense                                 | (104,274)                        | (1,420)   |
| - Super deduction for research and development expenses    | (1,131)                          | (2,671)   |
| Income tax expense   | 23                               | 604       |

#### Notes:

#### (a) Cayman Islands Income Tax

The Company is incorporated under the laws of the Cayman Islands as an exempted company with limited liability under the Companies Law of the Cayman Islands and accordingly is not subject to Cayman Islands income tax.

#### (b) Hong Kong Income Tax

Hong Kong income tax rate is 16.5%. No Hong Kong profits tax was provided for as there was no estimated assessable profit that was subject to Hong Kong profits tax during the six months ended 30 June 2024 and 30 June 2023.

#### (c) PRC Corporate Income Tax ("CIT")

The income tax provision of the Group in respect of its operations in PRC was calculated at the tax rate of 25% on the assessable profits, based on the existing legislation, interpretations and practices in respect thereof. According to the relevant tax circulars issued by the PRC tax authorities, some subsidiaries of the Group are entitled to certain tax concessions because they are small and micro enterprises.

#### (d) PRC withholding Tax ("WHT")

According to the New Corporate Income Tax Law ("New CIT Law"), distribution of profits earned by PRC companies since 1 January 2008 to foreign investors is subject to withholding tax of 5% or 10%, depending on the country of incorporation of the foreign investor, upon the distribution of profits to overseas-incorporated immediate holding companies. WHT of the Group was levied on the interests generated from term deposits and the loans advanced to related companies located in

The Group does not have any plan to require its PRC subsidiaries to distribute their retained earnings and intends to retain them to operate and expand its business in the PRC. Accordingly, no deferred income tax liability on WHT was accrued as at 30 June 2024 (as at 31 December 2023: nil).

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

### 12 EARNINGS/(LOSS) PER SHARE

(a) Basic earnings/(loss) per share for the six months ended 30 June 2024 and 2023 are calculated by dividing the earnings/(loss) attributable to the Company's equity holder by the weighted average number of ordinary shares in issue during the periods.

The calculation of earnings/(loss) per share is based on the following:

|   | For the six months ended 30 June 2024 2023 |                     |
|---|--|---------------------|
| Profit/(Loss) attributable to owners of the Company for the period  Weighted average number of ordinary shares in issue | 56,648                                     | (244,618)           |
| ('000)  | 1,083,504                                  | 1,079,651<br>(0.23) |
| Basic earnings/(loss) per share (RMB yuan)  | 0.05                                       |                     |

(b) Diluted earnings or loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares.

For the six months ended 30 June 2024, the Group has share options as potential dilutive ordinary shares which was included in the calculation of diluted earnings per share. As the Group incurred losses for the six months ended 30 June 2023, the potential ordinary shares were not included in the calculation of dilutive loss per share, as their inclusion would be anti-dilutive.

#### 13 GOODWILL

|   | As at 1 January<br>2024 and 30 June<br>2024 |
|---|---|
| Wanjia Healthcare                                   | 961,644                                     |
| Smart Health Business                               | 707,284                                     |
| Jiangxi Pingan Health Pharmacy Company Limited      | 5,119                                       |
| Pingan Yingjian                                     | 3,166                                       |
| Shanghai Mengchong Information Technology Co., Ltd. | 479   |
| Total   | 1,677,692                                   |
| Less: impairment losses                             | -   |
| Net book value                                      | 1,677,692                                   |

As at 30 June 2024, management reviewed the cash flow projections which was based on business plan and used to prepare goodwill impairment testing as at 31 December 2023. Management found no significant change on the business plan and did not identify any impairment indicators on goodwill.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 14 LEASES

#### (a) Amounts recognized in the statement of financial position

The statement of financial position shows the following amounts relating to leases:

|                     | As at 30 June<br>2024 | As at 31 December 2023 |
|---------------------|-----------------------|------------------------|
| Right-of-use assets |                       |                        |
| Properties          | 43,841                | 80,951                 |
| Lease liabilities   |                       |                        |
| Current             | 29,016                | 43,621                 |
| Non-current         | 19,734                | 49,989                 |
|                     | 48,750                | 93,610                 |

Additions to the cost of right-of-use assets during the six months ended 30 June 2024 were RMB4,156 thousand (during the six months ended 30 June 2023: RMB12,178 thousand).

#### (b) Amounts recognized in the income statement

The income statement shows the following amounts relating to leases:

|                                     | For the six months end | For the six months ended 30 June |  |
|-------------------------------------|------------------------|----------------------------------|--|
|                                     | 2024                   | 2023                             |  |
| Depreciation of right-of-use assets |                        |                                  |  |
| Properties                          | (21,887)               | (35,203)                         |  |
| Finance costs                       | (1,289)                | (3,798)                          |  |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

## 15 PROPERTY, PLANT AND EQUIPMENT

|                               | Office and telecommunication | Leasehold    |           |
|-------------------------------|------------------------------|--------------|-----------|
|                               | equipment                    | improvements | Total     |
| As at 1 January 2024          |                              |              |           |
| Cost                          | 328,365                      | 135,181      | 463,546   |
| Accumulated depreciation      | (270,495)                    | (107,369)    | (377,864) |
| Net book amount               | 57,870                       | 27,812       | 85,682    |
| Six months ended 30 June 2024 |                              |              |           |
| Opening net book amount       | 57,870                       | 27,812       | 85,682    |
| Additions                     | 8,291                        | 2,073        | 10,364    |
| Disposal                      | (2,318)                      | -            | (2,318)   |
| Depreciation charge           | (10,789)                     | (9,534)      | (20,323)  |
| Closing net book amount       | 53,054                       | 20,351       | 73,405    |
| As at 30 June 2024            |                              |              |           |
| Cost                          | 322,748                      | 137,254      | 460,002   |
| Accumulated depreciation      | (269,694)                    | (116,903)    | (386,597) |
| Net book amount               | 53,054                       | 20,351       | 73,405    |
| As at 1 January 2023          |                              |              |           |
| Cost                          | 321,970                      | 124,812      | 446,782   |
| Accumulated depreciation      | (249,903)                    | (85,411)     | (335,314) |
| Net book amount               | 72,067                       | 39,401       | 111,468   |
| Six months ended 30 June 2023 |                              |              |           |
| Opening net book amount       | 72,067                       | 39,401       | 111,468   |
| Additions                     | 7,702                        | 7,738        | 15,440    |
| Disposal                      | (1,818)                      | -            | (1,818)   |
| Depreciation charge           | (20,684)                     | (10,950)     | (31,634)  |
| Closing net book amount       | 57,267                       | 36,189       | 93,456    |
| As at 30 June 2023            |                              |              |           |
| Cost                          | 327,223                      | 132,550      | 459,773   |
| Accumulated depreciation      | (269,956)                    | (96,361)     | (366,317) |
| Net book amount               | 57,267                       | 36,189       | 93,456    |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

## 16 OTHER INTANGIBLE ASSETS

|                               | Software  | Licences | Total     |
|-------------------------------|-----------|----------|-----------|
| As at 1 January 2024          |           |          |           |
| Cost                          | 149,715   | 64,437   | 214,152   |
| Accumulated amortisation      | (110,892) | (41,202) | (152,094) |
| Accumulated impairment        | -         | (19,569) | (19,569)  |
| Net book amount               | 38,823    | 3,666    | 42,489    |
| Six months ended 30 June 2024 |           |          |           |
| Opening net book amount       | 38,823    | 3,666    | 42,489    |
| Amortisation                  | (10,043)  | (276)    | (10,319)  |
| Closing net book amount       | 28,780    | 3,390    | 32,170    |
| As at 30 June 2024            |           |          |           |
| Cost                          | 149,715   | 64,437   | 214,152   |
| Accumulated amortisation      | (120,935) | (41,478) | (162,413) |
| Accumulated impairment        | -         | (19,569) | (19,569)  |
| Net book amount               | 28,780    | 3,390    | 32,170    |
| As at 1 January 2023          | -         |          |           |
| Cost                          | 146,868   | 64,437   | 211,305   |
| Accumulated amortisation      | (83,539)  | (33,619) | (117,158) |
| Accumulated impairment        | _         | (19,569) | (19,569)  |
| Net book amount               | 63,329    | 11,249   | 74,578    |
| Six months ended 30 June 2023 |           |          |           |
| Opening net book amount       | 63,329    | 11,249   | 74,578    |
| Additions                     | 1,253     | _        | 1,253     |
| Amortisation                  | (14,032)  | (4,257)  | (18,289)  |
| Closing net book amount       | 50,550    | 6,992    | 57,542    |
| As at 30 June 2023            |           |          |           |
| Cost                          | 148,121   | 64,437   | 212,558   |
| Accumulated amortisation      | (97,571)  | (37,876) | (135,447) |
| Accumulated impairment        |           | (19,569) | (19,569)  |
| Net book amount               | 50,550    | 6,992    | 57,542    |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 17 INVESTMENTS IN ASSOCIATES AND JOINT VENTURES

|                                   | As at 30 June | As at 30 June As at 31 December |  |
|-----------------------------------|---------------|---------------------------------|--|
|                                   | 2024          | 2023                            |  |
| Investments in associates (a)     | 108,944       | 109,212                         |  |
| Investments in joint ventures (b) | -             | -                               |  |
|                                   | 108,944       | 109,212                         |  |

#### (a) Investments in associates

|                                       | For the six months en | For the six months ended 30 June |  |
|---------------------------------------|-----------------------|----------------------------------|--|
|                                       | 2024                  | 2023                             |  |
| At the beginning of the period        | 109,212               | 355,595                          |  |
| Share of losses in associates         | (268)                 | (1,395)                          |  |
| Share of other reserves of associates | -                     | 2,434                            |  |
| At the end of the period              | 108,944               | 356,634                          |  |

<sup>(</sup>i) As at 30 June 2024, the Group made an aggregate impairment provision of approximately RMB23,665 thousand (as at 31 December 2023: RMB23,665 thousand).

#### (b) Investments in joint ventures

As at 30 June 2024, the Group holds 51% equity interest of Ping An Haoyi (Xi'an Xincheng District) Comprehensive Outpatient Department Co., Ltd..

|                                   | For the six month | For the six months ended 30 June |  |
|-----------------------------------|-------------------|----------------------------------|--|
|                                   | 2024              | 2023                             |  |
| At the beginning of the period    | -                 | 1,020                            |  |
| Share of losses of joint ventures | -                 | (1,020)                          |  |
| At the end of the period          | -                 | -                                |  |

#### **18 INVENTORIES**

|                                     | <b>As at 30 June</b> As at 31 December <b>2024</b> 2023 |          |
|-------------------------------------|---|----------|
| Inventories stored in third parties | 81,547  | 46,426   |
| Goods in transit                    | 38,879  | 66,142   |
| Inventories in warehouse            | 22,371  | 104,460  |
| Less: impairment provision          | (16,863)  | (18,453) |
|                                     | 125,934   | 198,575  |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 19 TRADE RECEIVABLES

|                      | <b>As at 30 June</b> As at <b>2024</b> | 31 December<br>2023 |
|----------------------|--|---------------------|
| Medical services     | 811,834                                | 786,744             |
| Health services      | 273,190                                | 518,953             |
| Senior care services | 25,565                                 | 15,797              |
|                      | 1,110,589                              | 1,321,494           |
| Less: loss allowance | (153,906)                              | (131,102)           |
|                      | 956,683                                | 1,190,392           |

(a) Aging analysis of trade receivables based on invoice date is as follows:

|                      | As at 30 June<br>2024 | As at 31 December 2023 |
|----------------------|-----------------------|------------------------|
| Up to 3 months       | 738,284               | 1,051,927              |
| 3 to 6 months        | 138,996               | 51,803                 |
| 6 months to 1 year   | 66,679                | 70,933                 |
| 1 to 2 years         | 44,300                | 65,066                 |
| More than 2 years    | 122,330               | 81,765                 |
|                      | 1,110,589             | 1,321,494              |
| Less: loss allowance | (153,906)             | (131,102)              |
|                      | 956,683               | 1,190,392              |

As at 30 June 2024, approximately 9% of trade receivables aged more than one year are due from related parties.

#### (b) Fair values of trade receivables

Due to the short-term nature of the current receivables, their carrying amount is considered to be the same as their fair value.

#### (c) Impairment and risk exposure

The Group applies the IFRS 9 simplified approach to measure expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 20 PREPAYMENTS AND OTHER RECEIVABLES

|   | <b>As at 30 June</b> As at <b>2024</b> | 31 December<br>2023 |
|---|--|---------------------|
| Included in current assets                |  |                     |
| Advance payments                          | 116,873                                | 106,052             |
| Recoverable value-added tax               | 113,508                                | 116,167             |
| Deposits                                  | 67,658                                 | 68,618              |
| Amounts due from related parties (Note a) | 21,201                                 | 32,072              |
| Others                                    | 64,750                                 | 25,010              |
|   | 383,990                                | 347,919             |
| Less: loss allowance                      | (42,601)                               | -                   |
|   | 341,389                                | 347,919             |

#### Notes:

<sup>(</sup>a) During the period, the amounts due from related parties were of a non-trade nature.

<sup>(</sup>b) As at 30 June 2024, the carrying amounts of deposits and other assets (excludes advance payments and recoverable valueadded tax), were approximate to their fair values. The Group consider significant changes in the expected performance and behavior of the third party in business when assessed expected credit losses.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 21 FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

|                            | As at 30 June As at 31 December |           |
|----------------------------|---------------------------------|-----------|
|                            | 2024                            | 2023      |
| Included in current assets |                                 |           |
| Wealth management products | 5,383,595                       | 4,788,394 |
| Investment funds           | 555,339                         | 542,272   |
|                            | 5,938,934                       | 5,330,666 |

### 22 CASH AND CASH EQUIVALENTS, RESTRICTED CASH AND TERM **DEPOSITS**

#### (a) Cash and cash equivalents

|  | As at 30 June As at 31 December |           |
|--|---------------------------------|-----------|
|  | 2024                            | 2023      |
| Cash   | 225                             | 17        |
| Cash at bank   | 2,161,765                       | 1,596,509 |
| Short-term bank deposits with initial term within three months | 754,862                         | 201,360   |
| Other cash equivalents   | 91,803                          | 68,625    |
|  | 3,008,655                       | 1,866,511 |

Cash and cash equivalents are denominated in the following currencies:

|     | As at 30 June As | As at 30 June As at 31 December |  |
|-----|------------------|---------------------------------|--|
|     | 2024             | 2023                            |  |
| RMB | 2,922,821        | 1,776,663                       |  |
| USD | 63,351           | 65,902                          |  |
| HKD | 22,483           | 23,946                          |  |
|     | 3,008,655        | 1,866,511                       |  |

#### (b) Restricted cash

As at 30 June 2024, restricted deposits held at banks amounted to RMB75,074 thousand, of which RMB70,000 thousand is legally frozen due to litigation (Note 27).

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

### 22 CASH AND CASH EQUIVALENTS, RESTRICTED CASH AND TERM **DEPOSITS (Continued)**

#### (c) Term deposits

|   | As at 30 June As at 31 December 2024 2023 |           |
|---|---|-----------|
| Term deposits with initial term of over three months that will mature within one year | 2,141,383                                 | 3,910,825 |
| Term deposits with initial term of over three months that will mature over one year   | 1,370,000                                 | 1,170,000 |
| Interest receivable   | 111,919                                   | 268,156   |
| Less: loss allowance of term deposits   | (1,211)                                   | (3,040)   |
|   | 3,622,091                                 | 5,345,941 |

Term deposits are denominated in the following currencies:

|     | As at 30 June<br>2024 | As at 31 December<br>2023 |
|-----|-----------------------|---------------------------|
| RMB | 2,768,086             | 4,501,714                 |
| USD | 855,216               | 847,267                   |
|     | 3,623,302             | 5,348,981                 |

The weighted average effective interest rate of the term deposits of the Group as at 30 June 2024 is 3.91% (as at 31 December 2023: 3.95%).

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 23 SHARE CAPITAL

|   | Number of shares | USD    |
|---|------------------|--------|
| Authorised  |                  |        |
| Ordinary shares of USD0.000005 each at 1 January 2024 and |                  |        |
| 30 June 2024  | 10,000,000,000   | 50,000 |

|  | Number of shares | USD   | Equivalent to<br>RMB yuan |
|--|------------------|-------|---------------------------|
| Issued                                 |                  |       |                           |
| Ordinary shares of USD0.000005 each at |                  |       |                           |
| 1 January 2024 and 30 June 2024        | 1,118,812,900    | 5,594 | 35,067                    |

#### **24 RESERVES**

|   | As at 30 June<br>2024 | As at 31 December 2023 |
|---|-----------------------|------------------------|
|   | 2024                  | 2023                   |
| Other reserves                                      |                       |                        |
| - share-based payments - value of employee services | 274,387               | 246,063                |
| Reorganization (Note a)                             | 350,000               | 350,000                |
| Share premium                                       |                       |                        |
| - share premium from capital injection              | 19,662,022            | 19,662,022             |
| - share-based payments - value of employee services | 286,476               | 284,967                |
| - proceeds from exercise of share options           | 395,383               | 395,222                |
| Cancellation of shares                              | (593,985)             | (593,985)              |
| Currency translation differences                    | 147,767               | 139,375                |
| Partial disposal of equity interests of subsidiary  | 13,526                | 13,526                 |
| Other   | 576                   | 576                    |
|   | 20,536,152            | 20,497,766             |

#### Notes:

<sup>(</sup>a) PAHC was incorporated on 20 August 2014 with issued share capital of RMB350,000,000 divided into 350,000,000 ordinary shares of RMB1 each. For the purpose of introduction of overseas investors and preparation for a listing of the Company's shares on overseas capital markets, the Company and its shareholders underwent a series of reorganization (the "Reorganization"). After the Reorganization, PAHC is controlled by Kang Jian through the Contractual Arrangements. The share capital of RMB350,000,000 is treated as a deemed distribution from the owners.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 25 SHARE-BASED PAYMENTS

On 26 December 2014, an equity-settled share-based compensation plan was granted to employees with the objective to recognize and reward the contribution of the the eligible directors, employees and other persons (collectively, the "Grantees") for the growth and development of the Group (the "Share Option Plan"). The Share Option Plan is valid and effective for 10 years from the grant date. Upon the establishment of the Share Option Plan, 35,000,000 shares have been reserved by two shareholders of the Company, Glorious Peace and Bang Qi Jian Limited ("Bang Qi Jian"). Under the Share Option Plan, a special purpose vehicle named Hong Qi Jian Limited ("Hong Qi Jian"), was set up by Glorious Peace and Bang Qi Jian to hold shares contributed by Glorious Peace and Bang Qi Jian.

Le An Xin was incorporated on 17 October 2017 as a vehicle to replace Hong Qi Jian to hold the 35,000,000 ordinary shares for the Company's employees under the Share Option Plan, with no changes to the rest of the conditions and the Grantees of the Share Option Plan. As the Company has the power to govern the relevant activities of Le An Xin and can derive benefits from the services to be rendered by the Grantees, the directors of the Company consider it is appropriate to consolidate Le An Xin. The total number of shares pursuant to the Share Option Plan is 70,000,000 after considering the effect of the share subdivision upon the completion of the Listing.

Subject to the Grantees continuing to be a service provider, 100% of these options will be vested over 4 years upon fulfilling the service conditions and non-market performance conditions prescribed in the share option agreement.

The options should be exercised no earlier than 180 days before the Company successfully completes an initial public offering and the Company's shares listed in the stock exchange ("IPO and Listing") and no later than 30 days after the IPO and Listing. The vesting date is determined by the Board of Directors of the Company. On 20 January 2018, amendments to the Share Option Plan were approved by the directors of the Company and the vesting date was changed to no earlier than 180 days before IPO and Listing or no earlier than 12 months after IPO and Listing. On 27 February 2019, amendments to the Share Option Plan were approved by the directors of the Company: (1) the vesting date was changed to no earlier than 12 months after Listing; and (2) the vesting conditions of the nil-priced share options granted after 27 February 2019 were modified. The options vest in full or in part depending on the satisfaction of specified performance conditions, including growth rate of the share price of the Company and KPIs achievement of the Group as a whole and of the Grantees. The amendments impact the grant date fair value of nil-priced share option since the market condition needs to be considered.

Movements in the number of share options granted to employees are as follows:

|                                | Number of share options  For the six months ended 30 June  2024 2023 |             |
|--------------------------------|--|-------------|
|                                |  |             |
| At the beginning of the period | 11,651,148   | 26,260,813  |
| Exercised (Note a)             | (47,371)   | (746,745)   |
| Forfeited                      | (618,132)  | (6,612,290) |
| At the end of the period       | 10,985,645   | 18,901,778  |

#### Notes:

(a) During the six months ended 30 June 2024, 47,371 ordinary shares were exercised (six months ended 30 June 2023: 746,745 ordinary shares) at the total consideration of approximately RMB161 thousand (six months ended 30 June 2023: RMB4,606 thousand). The exercise prices range from RMB0 each to RMB5 each.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

### 25 SHARE-BASED PAYMENTS (continued)

Share options outstanding at the end of the period/year have the following expiry dates and exercise prices:

| Grant Year | Expiry Year | Exercise price | Number of share As at 30 June As a |            |
|------------|-------------|----------------|------------------------------------|------------|
|            |             | (RMB yuan)     | 2024                               | 2023       |
| 2014       | 2024        | 0.50           | -                                  | -          |
| 2015       | 2025        | 0.50-0.75      | 85,174                             | 85,174     |
| 2016       | 2026        | 5.00           | 98,100                             | 105,300    |
| 2017       | 2027        | 23.50-32.00    | 2,111,996                          | 2,113,681  |
| 2019       | 2029        | 0-30.95        | 760,724                            | 771,993    |
| 2020       | 2030        | 0              | 659,343                            | 707,911    |
| 2021       | 2031        | 0              | 789,750                            | 789,750    |
| 2022       | 2032        | 0              | 6,180,558                          | 6,777,339  |
| 2023       | 2033        | 0              | 300,000                            | 300,000    |
|            |             |                | 10,985,645                         | 11,651,148 |

Before the Listing, the Company used the discounted cash flow method to determine the underlying equity fair value of the Company and adopted equity allocation model to determine the fair value of the underlying ordinary shares. Key assumptions, such as discount rate and projections of future performance, were required to be determined by the Company with best estimate. Based on fair value of the underlying ordinary shares, the Company used Binomial option-pricing model to determine the fair value of the share options on the grant date.

After the Listing, the fair value of the awarded share options was calculated by reference to the market price of the Company's shares at the respective grant date. For those nil-priced options with market-based performance conditions, the fair value is calculated using a Monte-Carlo simulation model. The Monte-Carlo simulation model reflected the historical volatility of the Company's share price and those of all other companies to which the Company's performance would be compared, over a period equal to the vesting period of the awards.

During the six months ended 30 June 2024, the Group recorded share-based payments of approximately RMB29,833 thousand (six months ended 30 June 2023: RMB5,912 thousand) related to the Share Option Plan.

The average remaining contractual life of share options outstanding as at 30 June 2024 and 31 December 2023 is 6.7 years and 7.3 years respectively.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 26 TRADE AND OTHER PAYABLES

|   | As at 30 June As a | As at 30 June As at 31 December |  |
|---|--------------------|---------------------------------|--|
|   | 2024               | 2023                            |  |
| Included in current liabilities         |                    |                                 |  |
| Trade payables (Note a)                 | 542,352            | 741,453                         |  |
| Wages payables                          | 434,603            | 573,155                         |  |
| Accrued expenses                        | 256,288            | 388,693                         |  |
| Amounts due to suppliers                | 143,457            | 147,365                         |  |
| Tax payables                            | 116,329            | 102,957                         |  |
| Amounts due to related parties          | 59,270             | 46,201                          |  |
| Agent business related payables         | 53,075             | 30,158                          |  |
| Others                                  | 101,728            | 171,389                         |  |
|   | 1,707,102          | 2,201,371                       |  |
| Included in non-current liabilities     |                    |                                 |  |
| Amounts due to related parties (Note b) | 11,242             | 10,990                          |  |

(a) Aging analysis of trade payables based on recorded date is as follows:

|                    | As at 30 June<br>2024 | As at 31 December 2023 |
|--------------------|-----------------------|------------------------|
| Up to 3 months     | 426,529               | 690,571                |
| 3 to 6 months      | 15,042                | 21,799                 |
| 6 months to 1 year | 80,165                | 12,132                 |
| 1 to 2 years       | 17,092                | 12,547                 |
| More than 2 years  | 3,524                 | 4,404                  |
|                    | 542,352               | 741,453                |

(b) As at 30 June 2024, Pingan Yingjian, a subsidiary of the Group, has a long-term borrowing of RMB10,500 thousand with original duration of 36 months from its shareholder Yingjian Enterprise Management Consulting (Shanghai) Co., Ltd. ("Yingjian Enterprise Management Consulting"), which is unsecured and bears interest rate of 4.75%,

#### **27 PROVISIONS**

|                                    | As at 30 June As at 31 December |        |
|------------------------------------|---------------------------------|--------|
|                                    | 2024                            | 2023   |
| Provision for litigations (Note a) | 95,000                          | 95,000 |

(a) As at 30 June 2024, the Group was the defendant in certain outstanding litigations. Combining with fact and the progress, as well as the opinions of the internal and external legal counsels, the Group recognized the estimated losses from such litigations and disputes as provisions. The Group believes that the provisions are reasonable and sufficient. The above cases are still under trial and the Group considers that the disclosure of case details will have an uncertain impact on the outstanding cases, and therefore has not disclosed the case details. Although the above provision was made, it does not represent the recognition of losses by the Group. The Group will spare no effort to maintain the overall interests of the company and shareholders.

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

#### 28 DIVIDENDS

No dividends have been paid or declared by the Company during the six months ended 30 June 2024 (six months ended 30 June 2023: nil).

#### 29 RELATED PARTY TRANSACTIONS

Save as those disclosed in the other notes, the following significant transactions were carried out between the Group and its related parties. In the opinion of the directors of the Company, the related party transactions were carried out in the normal course of business and at terms negotiated between the Group and the respective related parties. The Group's pricing policies of the transactions with related parties are determined on the basis of mutual negotiations between the relevant parties.

#### (a) Names of and relationships with related parties

| Name of related parties  | Relationship with the Company                               |
|--|---|
| Glorious Peace   | A shareholder that has significant influence over the Group |
| Ping An  | Ultimate parent company of Glorious Peace                   |
| Ping An Life Insurance Company of China, Ltd. ("Ping An Life Insurance")                               | Controlled by Ping An                                       |
| Ping An Health Insurance Company of China, Ltd. ("Ping An Health Insurance")                           | Controlled by Ping An                                       |
| Ping An Property & Casualty Insurance Company of China, Ltd. ("Ping An Property & Casualty Insurance") | Controlled by Ping An                                       |
| Ping An Bank Co., Ltd. ("Ping An Bank")  | Controlled by Ping An                                       |
| Ping An Annuity Insurance Company of China, Ltd. ("Ping An Annuity Insurance")                         | Controlled by Ping An                                       |
| Shenzhen Ping An Financial Services Co., Ltd. ("Ping An Financial Services")                           | Controlled by Ping An                                       |
| Shenzhen Wanlitong Network Information Technology Co., Ltd. ("Shenzhen Wanlitong")                     | Controlled by Ping An                                       |
| Ping An Pay Technology Service Co., Ltd. ("Ping An Pay Tech")  | Controlled by Ping An                                       |
| Ping An Technology (Shenzhen) Co., Ltd. ("Ping An Technology")   | Controlled by Ping An                                       |
| Shanghai An Yi Tong Electronic Commerce Co., Ltd. ("Shanghai An Yi Tong")                              | Controlled by Ping An                                       |
| Ping An Yi Qian Bao Electronic Commerce Co., Ltd. ("Ping An Yiqianbao")                                | Controlled by Ping An                                       |
| Shenzhen Ping An Communication Technology Co., Ltd. ("Ping An Communication Technology")               | Controlled by Ping An                                       |
| Shanghai Zean Investment Management Co., Ltd. ("Zean Investment")                                      | Controlled by Ping An                                       |
| Ping An International Financial Leasing Company Limited ("Ping An Financial Leasing")                  | Controlled by Ping An                                       |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

## 29 RELATED PARTY TRANSACTIONS (Continued)

#### (a) Names of and relationships with related parties (Continued)

| Name of related parties   | Relationship with the Company                |
|---|--|
| Shenzhen Ping An Properties Investment Co., Ltd. ("Ping An<br>Properties")                        | Controlled by Ping An                        |
| Ping An Fund Management Co., Ltd ("Ping An Fund")   | Controlled by Ping An                        |
| Ping An Asset Management Co. Ltd ("Ping An Asset<br>Management")                                  | Controlled by Ping An                        |
| Ping An Wealth Management Co. Ltd ("Ping An Wealth<br>Management")                                | Controlled by Ping An                        |
| Ping An Haoyi (Wuhan) Comprehensive Outpatient Department<br>Co., Ltd. ("Haoyi (Wuhan)")          | Controlled by Ping An                        |
| Chongqing Pingan Haoyi Jingwei Comprehensive Outpatient<br>Service Co., Ltd. ("Chongqing Haoyi")  | Controlled by Ping An                        |
| Nanchang Ping'an Haoyi Health Examination Center Co., Ltd.<br>("Nanchang Haoyi")                  | Controlled by Ping An                        |
| Shanghai Ping An Haoyi Chuangzhi Outpatient Department Co.,<br>Ltd. ("Shanghai Haoyi")            | Controlled by Ping An                        |
| Guangzhou Pingan Haoyi Health Examination Center Co., Ltd.<br>("Guangzhou Haoyi")                 | Controlled by Ping An                        |
| Kiamen Ping An Haoyi Outpatient Department Co., Ltd. ("Xiamen Haoyi")                             | Controlled by Ping An                        |
| Shenyang Heping Ping An Haoyi Comprehensive Outpatient<br>Department Co., Ltd. ("Shenyang Haoyi") | Controlled by Ping An                        |
| Ping An Haoyi (Qingdao) Comprehensive Outpatient Department<br>Co., Ltd. ("Haoyi (Qingdao)")      | Controlled by Ping An                        |
| Shanghai Geying Enterprise Management Co., Ltd. ("Shanghai<br>Geying")                            | Controlled by Ping An                        |
| Beijing Jinkun Lize Real Estate Co., Ltd. ("Beijing Jinkun Lize")                                 | Controlled by Ping An                        |
| Yingjian Enterprise Management Consulting   | Shareholder of the subsidiary of th<br>Group |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

## 29 RELATED PARTY TRANSACTIONS (Continued)

## (b) Significant transactions with related parties

|                                       | For the six months en | For the six months ended 30 June |  |
|---------------------------------------|-----------------------|----------------------------------|--|
|                                       | 2024                  | 2023                             |  |
| Trademark licensing                   |                       |                                  |  |
| Ping An                               | -                     | _                                |  |
| Provision of products and services    |                       |                                  |  |
| Ping An Life Insurance                | 213,111               | 186,782                          |  |
| Ping An Property & Casualty Insurance | 85,422                | 206,809                          |  |
| Ping An Health Insurance              | 66,963                | 40,348                           |  |
| Ping An Bank                          | 40,168                | 92,120                           |  |
| Ping An Annuity Insurance             | 16,417                | 11,409                           |  |
| Shanghai An Yi Tong                   | 11,139                | 24,265                           |  |
| Shenzhen Wanlitong                    | 7,057                 | 4,385                            |  |
| Ping An Financial Leasing             | 3,677                 | 4,998                            |  |
| Ping An Financial Services            | 1,608                 | 2,710                            |  |
| Ping An Fund                          | 1,232                 | 1,591                            |  |
| Services purchasing                   |                       |                                  |  |
| Ping An Pay Tech                      | 61,895                | 48,065                           |  |
| Ping An Health Insurance              | 29,295                | 28,941                           |  |
| Ping An Property & Casualty Insurance | 23,326                | 27,046                           |  |
| Ping An Communication Technology      | 21,639                | 29,042                           |  |
| Ping An Financial Services            | 16,859                | 11,993                           |  |
| Ping An Technology                    | 16,365                | 14,668                           |  |
| Chongqing Haoyi                       | 9,007                 | 8,740                            |  |
| Haoyi (Qingdao)                       | 8,527                 | 4,186                            |  |
| Shanghai Haoyi                        | 7,883                 | 1,723                            |  |
| Ping An Bank                          | 7,686                 | 30,316                           |  |
| Xiamen Haoyi                          | 7,552                 | 7,713                            |  |
| Haoyi (Wuhan)                         | 6,531                 | 7,024                            |  |
| Shenzhen Wanlitong                    | 5,722                 | 13,171                           |  |
| Shenyang Haoyi                        | 5,703                 | 4,188                            |  |
| Guangzhou Haoyi                       | 5,041                 | 4,822                            |  |
| Nanchang Haoyi                        | 4,252                 | 3,484                            |  |
| Ping An                               | 3,123                 | 3,255                            |  |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

## 29 RELATED PARTY TRANSACTIONS (Continued)

## (b) Significant transactions with related parties (Continued)

|                                | For the six months end | For the six months ended 30 June |  |
|--------------------------------|------------------------|----------------------------------|--|
|                                | 2024                   | 2023                             |  |
| Deposit interests              |                        |                                  |  |
| Ping An Bank                   | 14,094                 | 25,981                           |  |
| Investment income              |                        |                                  |  |
| Ping An Wealth Management      | 17,014                 | -                                |  |
| Ping An Bank                   | 11,989                 | 8,528                            |  |
| Ping An Asset Management       | 7,371                  | 26,406                           |  |
| Ping An Properties             | -                      | 12,077                           |  |
| Property leasing expenses paid |                        |                                  |  |
| Zean Investment                | 2,131                  | 12,146                           |  |
| Shanghai Geying                | 1,575                  | 1,889                            |  |
| Beijing Jinkun Lize            | 1,166                  | 1,422                            |  |

#### (c) Period/Year end balances with related parties

|   | As at 30 June | As at 31 December |
|---|---------------|-------------------|
|   | 2024          | 2023              |
| Cash and cash equivalents and term deposits           |               |                   |
| Ping An Bank  | 2,126,198     | 2,419,348         |
| Ping An Pay Tech                                      | 66,736        | 58,151            |
| Restricted cash                                       |               |                   |
| Ping An Bank  | 75,074        | 84,796            |
| Financial assets at fair value through profit or loss |               |                   |
| Ping An Bank  | 1,635,103     | 200,146           |
| Ping An Wealth Management                             | 1,252,382     | 601,390           |
| Ping An Asset Management                              | -             | 801,865           |
| Ping An Fund  | -             | 503,316           |
| Trade receivables                                     |               |                   |
| Ping An Property& Casualty Insurance                  | 215,175       | 323,162           |
| Ping An Life Insurance                                | 187,668       | 159,814           |
| Ping An Health Insurance                              | 96,891        | 21,750            |
| Ping An Yiqianbao                                     | 50,626        | 283,155           |
| Ping An Bank  | 33,791        | 114,536           |
| Ping An Annuity Insurance                             | 19,314        | 11,724            |
| Ping An Financial Leasing                             | 13,302        | 13,611            |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

## 29 RELATED PARTY TRANSACTIONS (Continued)

### (c) Period/Year end balances with related parties (Continued)

|   | As at 30 June As at 2024 | 31 December<br>2023 |
|---|--------------------------|---------------------|
| Prepayments and other receivables         |                          |                     |
| Advance payments                          |                          |                     |
| Ping An Health Insurance                  | 593                      | 1,193               |
| Deposits in security                      |                          |                     |
| Ping An Technology                        | 40,275                   | 40,275              |
| Zean Investment                           | 3,011                    | 3,120               |
| Ping An Life Insurance                    | 2,947                    | 3,042               |
| Amounts due from related parties          |                          |                     |
| Ping An Health Insurance                  | 7,276                    | 7,279               |
| Ping An Property & Casualty Insurance     | 2,473                    | 2,463               |
| Ping An Life Insurance                    | 1,494                    | 1,494               |
| Trade and other payables                  |                          |                     |
| Ping An Technology                        | 15,251                   | 14,917              |
| Ping An Communication Technology          | 14,584                   | 4,823               |
| Yingjian Enterprise Management Consulting | 11,194                   | 10,942              |
| Ping An Property & Casualty Insurance     | 8,275                    | 8,148               |
| Ping An Financial Services                | 4,440                    | 3,154               |
| Ping An Pay Tech                          | 3,124                    | 560                 |

For the six months ended 30 June 2024

(All amounts expressed in RMB thousand unless otherwise stated)

### 29 RELATED PARTY TRANSACTIONS (Continued)

#### (c) Period/Year end balances with related parties (Continued)

Apart from the interest receivables generated from term deposits and financial assets at fair value through profit or loss due from Ping An Bank calculated based on deposit interest rates, the other balances including other prepayments and other receivables, trade receivables and deposits due from related parties are unsecured, interest-free and repayable on demand.

Apart from the borrowing from Yingjian Enterprise Management Consulting, the balances of trade and other payables due to related parties are unsecured, interest-free and repayable on demand.

#### 30 CONTINGENCIES

Save as the provisions disclosed in Note 27, there were no other material contingencies need to be disclosed as at 30 June 2024.

#### 31 SUBSEQUENT EVENTS

There were no material subsequent events need to be disclosed during the period from 30 June 2024 to the approval date of the interim consolidated financial information by the Board of Directors on 20 August 2024.

#### 32 COMPARATIVE FIGURES

Certain comparative figures have been reclassified or restated to conform to the interim condensed consolidated financial information's presentation.

#### 33 APPROVAL OF THE FINANCIAL INFORMATION

The interim condensed consolidated financial information was approved and authorized for issue by the Board of Directors of the Company on 20 August 2024.

In this interim report, unless the context otherwise requires, the following expressions shall have the following meanings:

| "Audit and Risk Management<br>Committee"        | Audit and Risk Management Committee under the Board  |
|---|--|
| "Bang Qi Jian"                                  | Bang Qi Jian Limited (幫騏鍵有限公司), a company incorporated under the laws of BVI on 10 November 2014   |
| "Bank"/"Ping An Bank"                           | Ping An Bank Co., Ltd. (平安銀行股份有限公司), a company incorporated under the laws of the PRC on 22 December 1987 whose shares are listed on the Shenzhen Stock Exchange (SZSE: 000001), and a subsidiary of Ping An |
| "Board"   | the board of directors of the Company  |
| "Company", "the Company" or<br>"Ping An Health" | Ping An Healthcare and Technology Company Limited (平安健康醫療科技有限公司), an exempted company incorporated in the Cayman Islands with limited liability on 12 November 2014  |
| "connected person(s)"                           | has the meaning ascribed to it under the Listing Rules   |
| "Controlling Shareholder(s)"                    | has the meaning ascribed to it under the Listing Rules   |
| "Corporate Governance Code"                     | the Corporate Governance Code as set out in Appendix C1 to the Listing<br>Rules  |
| "Director(s)"                                   | the director(s) of the Company   |
| "EIS Option(s)"                                 | the option(s) granted and to be granted to the Directors and employees of the Group under the Employee Incentive Scheme  |
| "EIS Share(s)"                                  | the Share(s) under the EIS Options which are directly held by Le An Xin  |
| "Employee Incentive Scheme" or                  | the scheme adopted by the Company on 26 December 2014, as amended  |

targets

"EIS"

or otherwise modified from time to time, to grant options to the incentive

| "Glorious Peace"                                 | Glorious Peace Limited (安鑫有限公司), a company incorporated under the laws of BVI on 10 November 2014, an indirect wholly-owned subsidiary of Ping An and our Controlling Shareholder  |
|--|--|
| "Group", "the Group", "we", "us" or<br>"our"     | the Company, its subsidiaries and the Operating Entities or, where the context so requires, in respect of the period prior to the Company becoming the holding company of its present subsidiaries, such subsidiaries as if they were subsidiaries of the Company at the relevant time |
| "Health Insurance"/"Ping An Health<br>Insurance" | Ping An Health Insurance Company Ltd. (平安健康保險股份有限公司), a company incorporated under the laws of the PRC on 13 June 2005 and a subsidiary of Ping An   |
| "HK\$"   | Hong Kong dollars, the lawful currency of Hong Kong  |
| "Hong Kong Share Registrar"                      | Computershare Hong Kong Investor Services Limited  |
| "Hong Kong" or "HK"                              | the Hong Kong Special Administrative Region of the People's Republic of China  |
| "IFRS"   | International Financial Reporting Standard   |
| "Independent Third Party(ies)"                   | has the meaning ascribed to it under the Listing Rules   |
| "Kang Jian"                                      | Kang Jian Information Technology (Shenzhen) Co., Ltd. (康鍵信息技術(深圳)有限公司), a company incorporated under the laws of the PRC on 13 February 2015 and a wholly-owned subsidiary of the Company  |
| "Le An Xin"                                      | Le An Xin (PTC) Limited, a company incorporated under the laws of BVI on 17 October 2017   |
| "Life Insurance"/"Ping An Life<br>Insurance"     | Ping An Life Insurance Company of China, Ltd. (中國平安人壽保險股份有限公司), a company incorporated under the laws of the PRC on 17 December 2002 and a subsidiary of Ping An   |
| "Listing"  | the listing of the Shares on the Main Board of the Stock Exchange  |
| "Listing Date"                                   | 4 May 2018, the date on which the Shares were listed and on which dealings in the Shares were first permitted to take place on the Stock Exchange  |
| "Listing Rules"                                  | the Rules Governing the Listing of Securities on The Stock Exchange of   |

"Main Board" the stock market (excluding the option market) operated by the Stock

Exchange which is independent from and operated in parallel with the

GEM of the Stock Exchange

"Managed Care" providing particular individual with comprehensive healthcare services in

exchange for fixed pre-paid premiums

"Model Code" Model Code for Securities Transactions by Directors of Listed Issuers

"Nomination and Remuneration

Committee"

Nomination and Remuneration Committee under the Board

"Online to Offline" and "Offline to Online" "020"

"Operating Entities" the entities we control through the contractual arrangements, namely

Ping An Health Cloud and its subsidiaries

"Paying users" users who purchase products and/or services on our platform via apps,

WAP (Wireless Application Protocol) or plug-ins at least once during a

period of time

"Ping An"/"Ping An Insurance

(Group)"

Ping An Insurance (Group) Company of China, Ltd. (中國平安保險(集團)股 份有限公司), a company incorporated under the laws of the PRC whose shares are dually listed on the Shanghai Stock Exchange and the Stock Exchange (SSE: 601318; SEHK: 2318). It is our Controlling Shareholder

"Ping An Annuity" Ping An Annuity Insurance Company Ltd. (平安養老保險股份有限公司), a

company incorporated under the laws of the PRC on 13 December 2004

and a subsidiary of Ping An

"Ping An Asset Management" Ping An Asset Management Co., Ltd. (平安資產管理有限責任公司), a

company incorporated under the laws of the PRC on 27 May 2005, a

subsidiary of Ping An

"Ping An Group" Ping An and its subsidiaries

"Ping An Health Cloud" or "PAHC" Ping An Health Cloud Company Limited (平安健康互聯網股份有限公司), a

company incorporated under the laws of the PRC on 20 August 2014 and

one of our Operating Entities

"Pingan Yingjian" Pingan Yingjian Medical Management (Shanghai) Limited (平安盈健醫療

> 管理(上海)有限公司), a company incorporated under the laws of the PRC on 24 April 2015, a subsidiary of Ping An Health Cloud and one of our

Operating Entities

"Property & Casualty Insurance"/ "Ping An Property & Casualty

Insurance"

Ping An Property & Casualty Insurance Company of China, Ltd. (中國平安 財產保險股份有限公司), a company incorporated under the laws of the PRC

on 24 December 2002 and a subsidiary of Ping An

"Prospectus" the prospectus of the Company dated 23 April 2018

"Reporting Period" the six months ended 30 June 2024

"RMB" or "Renminbi" Renminbi, the lawful currency of China

"SFO" the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong

Kong), as amended, supplemented or otherwise modified from time to

"Share(s)" ordinary share(s) in the share capital of the Company with a par value

of USD0.00001 each before share subdivision and with a par value of

USD0.000005 each after share subdivision

"Shareholder(s)" holder(s) of the Shares

"Stock Exchange" The Stock Exchange of Hong Kong Limited

"subsidiary(ies)" has the meaning ascribed to it under the Listing Rules

"substantial shareholder(s)" has the meaning ascribed to it under the Listing Rules

"USD" United States dollars, the lawful currency of the United States

"Yingjian Enterprise Management

Consulting"

Yingjian Enterprise Management Consulting (Shanghai) Co., Ltd. (盈健企 業管理諮詢(上海)有限公司), a company incorporated under the laws of the

PRC on 19 December 2014 and one of the shareholders of Pingan Yingjian

"%" per cent